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ABSTRACT OF THE DISSERTATION
Generation and Utilization of Diverse Memory B Cells After Flavivirus Challenges
by
Rachel Wong
Doctor of Philosophy in Biology and Biomedical Sciences
Immunology
Washington University in St. Louis, 2020
Professor Deepta Bhattacharya, Chair
Professor Paul Allen, Co-Chair
Over the course of an effective immune response to an infection, two distinct B cell
populations are generated to provide protection against reinfection, long-lived plasma cells
(LLPCs) and memory B cells (MBCs). LLPCs and MBCs originate from germinal center (GC)
B cells that have undergone B cell receptor (BCR) affinity maturation through iterative rounds of
somatic hypermutation, proliferation, and selection. Thus, LLPCs and MBCs can bind to their
antigen with higher affinity than their naïve B cell precursors. LLPCs constitutively secrete
antibodies and can provide sterilizing immunity that pre-exists subsequent infections. MBCs, on
the other hand, are quiescent and provide protection only after being re-activated. Re-activation
of MBCs can result either in the re-initiation of GC reactions to mold and affinity mature BCRs
toward new specificities or in the differentiation into plasma cells. However, the likelihood of
re-activating MBCs in the presence of pre-existing serum antibodies secreted by LLPCs is low.
Thus, the etiological role of MBCs is not well defined. We previously showed that MBCs are
capable of recognizing pathogen escape mutants that have evaded serum neutralization by

viii

antibodies secreted from LLPCs, though it is unclear the breadth of diverse antigens recognized
by MBCs.
Here, we demonstrate that the diversity of MBCs extends to recognizing heterologous
antigens. Using mouse models of sequential heterologous flavivirus vaccinations and activation
induced cytidine deaminase conditional knockout mice in which affinity maturation is ablated,
we observed that MBCs respond to heterologous antigens without further affinity maturation and
remodeling of their BCRs. Instead, MBCs respond by directly differentiating into plasma cells
to secrete antibodies, some of which are neutralizing, targeting the secondary pathogen. Thus,
the diversity of MBCs generated after a primary response dictates the response to subsequent
heterologous challenges.

Mechanistically, this diversity results from the continued, active

recruitment of low affinity germinal center B cells into the MBC pool.
Given the different roles of LLPCs and MBCs upon secondary challenge by either a
homologous or heterologous pathogen, understanding the durability of LLPC and MBC recall
responses can provide insights on how to modulate length of responses. We previously showed
that two members of the Broad complex, tramtrack, bric-a-brac-poxvirus, and zinc finger (BTBPOZ) family of transcription factors, ZBTB20 and ZBTB32, regulate distinct aspects of B cell
memory responses. ZBTB20 regulates adjuvant-dependent survival of long-lived plasma cells,
while ZBTB32 regulates the durability of recall response. Although the mechanisms of how
ZBTB20 and ZBTB32 regulate responses is unclear, the N-terminal BTB-POZ domain likely
recruits transcriptional repressors to different areas of DNA binding mediated by the C-terminal
zinc finger domains. Thus, we hypothesized that ZBTB38, another member of the BTB-POZ
family, may also regulate B cell responses. Using a mouse model in which ZBTB38 is deleted in

ix

hematopoietic cells, we demonstrate that ZBTB38 is dispensable for both primary and recall
responses to a hapten immunogen.
Taken together, we propose that the MBC diversity after a primary response is generated
by the continued, but active, selection of low affinity germinal center B cells into the MBC pool,
and that this diversity is directly utilized upon secondary challenges without further affinity
maturation. In addition, both the primary B cell and MBC recall responses do not require
expression of ZBTB38. Further work needs to be done defining the recall responses of MBCs to
live viruses and cues that promote the continuous selection of low-affinity GC B cells into the
MBC compartment.
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Chapter 1:
Introduction

The contents of this chapter have been previously published in Immunology. Personal
contributions include writing and editing this review in collaboration with Deepta Bhattacharya.

Wong R and Bhattacharya D. (2019), Basics of memory B‐cell responses: lessons from and for
the real world. Immunology, 156: 120-129. doi:10.1111/imm.13019

1

Protective immunity elicited by almost all vaccines and many infections is mediated by
pathogen-specific B cells and antibodies. The generation of such protective cells and antibodies
is mediated by a process of clonal expansion and diversification of fates, followed by a
contraction to the essential components of durable immunity. For T cell-dependent responses,
naïve B lymphocytes that recognize cognate antigens rapidly proliferate and differentiate into
short-lived plasma cells or germinal center B cells 1. Short-lived plasma cells secrete lowaffinity antibodies that are important for the initial defense against pathogens such as West Nile
virus

2, 3

, and are thought to live for only several days 4. Germinal center B cells progressively

affinity mature their B cell receptors through multiple rounds of somatic hypermutation and
selection 5, 6, 7. Cells carrying affinity-enhancing mutations can then differentiate into memory B
cells or long-lived plasma cells 8, 9.
Long-lived plasma cells constitutively secrete affinity-matured antibodies that pre-exist
subsequent infections, thereby providing sterilizing immunity 10, 11. These long-lived plasma cells
can live up to an entire human lifetime in the absence of cellular division 12. Yet their persistence
varies greatly with the specific infection or vaccine for reasons that still remain unclear.
Metabolic, but not transcriptional pathways appear to be the major determinants of plasma cell
longevity

13, 14

, but how infection- or vaccine-specific properties such as antigen avidity, innate

immune activation, and T cell help influence these programs remain unknown. Pathogens that
evade pre-existing serum antibodies may be recognized by memory B cells, which make up a
second line of defense

15, 16

. Memory B cells are quiescent, do not require continued antigenic

stimulation for survival, and are more easily reactivated than are their naïve counterparts

17, 18

.

The molecular and cellular details of memory B cell development have been recently reviewed

2

19, 20

and thus the focus of this article will be on memory B cells during recall responses in the

context of real-world infections.
During a recall response, reactivated memory B cells can differentiate into antibodysecreting cells and/or germinal center B cells, depending on the responding subpopulation. In
mice, memory B cell subpopulations were initially distinguished by immunoglobulin isotype
expression 21, 22. These studies showed that IgG+ memory B cells preferentially generate plasma
cells, whereas IgM+ cells re-initiate germinal center reactions. Subsequent studies reported that
CD80 and PD-L2 expression on antigen-specific cells are functional markers that distinguish
memory subsets irrespective of isotype

23

. CD80+PD-L2+ cells are poised to differentiate into

antibody-secreting cells, CD80-PD-L2- cells robustly differentiate into germinal center B cells,
and CD80-PD-L2+ cells possess an intermediate ability to differentiate into antibody secreting
cells and re-initiate germinal center reactions. These markers mostly, but not fully correlate with
IgM (enriched in the CD80-PD-L2-) or IgG (enriched in the CD80+PD-L2+) usage. Moreover, the
specific isotype used by memory B cells correlates with unique transcriptional programs that
support function and development 24. It is likely that the isotype is a marker of the innate signals
received by memory B cells during ontogeny rather than a causative determinant of a specific
transcriptional program

25

. In humans, memory B cells are identified based on CD27

26, 27

expression , and as in mice, their fate upon reactivation can be predicted by surface Ig
expression. Similar to mouse memory B cell subpopulations, IgG+ human memory B cells are
poised to differentiate into antibody secreting cells, and IgM+ memory B cells are predisposed to
form germinal center-like cells ex vivo 28. This correlation is reassuring, as mouse models allow
for a deeper mechanistic understanding of cellular behavior, whereas studies in humans bring a
real-world relevance to these findings. Another memory B cell subset, atypical memory B cells,
3

has been identified in tonsils 29. These cells express neither CD27 nor CD21, and express high
levels of inhibitory receptor FcRL4 or FcRL5

29, 30

. These cells tend to be hyporesponsive to

BCR stimulation, and are expanded in the blood in chronic infections like malaria and HIV 31, 32.
Understanding the recall behavior of each memory B cell subpopulation in different infections is
important for determining how to establish protective immunity, particularly when faced with the
challenge of vaccinating a population that is already partially immune to an endemic pathogen.
Here, we focus on flavivirus and Plasmodium infections as they pose some unique
challenges for generating immunity. As a result, there are interesting lessons to be applied to the
basic study of memory B cells. Reciprocally, principles from the cell biology of memory B cells
can be potentially applied to vaccination efforts. As examples of the challenges that these
globally relevant pathogens pose, infections of flavivirus-immune individuals by heterologous or
heterotypic strains can result in markedly exacerbated symptoms compared to the primary
challenge. Malaria, caused by Plasmodium infections, is characterized by the lack of a durable
antibody response, and requires multiple exposures to develop naturally acquired immunity. For
each infection, we will discuss the underlying antibody and memory B cell responses, speculate
on the ideal memory B cell response that considers the challenges faced, and conclude on
implications for vaccine design and remaining questions. We fully acknowledge that many
aspects of this review are speculative. Yet we believe it is imperative to apply the fundamentals
of memory B cell biology to contemporary, problematic infections to better guide vaccine design
and future research.
1.1 Flavivirus pathogenesis, epidemiology, and immunity
Flaviviruses present a global threat to public health, especially with the recent emergence
of epidemic Zika virus (ZIKV). Among many relatives, members of the Flavivirus genus
4

include the human pathogens ZIKV, West Nile Virus (WNV), Dengue virus (DENV), and
Japanese Encephalitis virus (JEV). These viruses are mainly transmitted by mosquitoes, and for
WNV and JEV, humans are a dead-end host. For the epidemic pathogens YFV, DENV, and
ZIKV, viral titers in humans can reach sufficient levels that these pathogens can be retransmitted by mosquitoes or by direct human-human contact

33, 34

.

Most infections are

asymptomatic or present mild symptoms, such as fever, arthralgia, and myalgia. However, some
cases of severe symptoms, such as severe hemorrhagic fever and vascular leakage, have been
reported.

These severe symptoms have been largely associated with secondary DENV

infections.
DENV has four serotypes, DENV1 to DENV4, all of which co-circulate in the same
geographic regions. Work by Sabin in the 1950s showed that DENV infection by one serotype
provided lifelong protection against homotypic infection, but not against heterotypic infections
35

. Indeed, heterotypic infections increase the severity of symptoms when infections occur after

antibodies generated from the primary challenge waned

36

.

Thus, primary DENV infection

generates a durable, serotype-specific antibody response that can be harmful to the host upon
heterotypic challenge. The increased severity of secondary infections is thought to be mediated
by antibody-dependent enhancement (ADE), a process whereby antibodies that neutralize poorly,
either due to epitope specificity or insufficient concentrations, enhance viral uptake via Fc
gamma receptors on mononuclear phagocytes

37, 38, 39

. In addition to the humoral contribution

(ADE) to increased disease severity upon heterologous infection, there is also a cellular
contribution termed original antigen sin (OAS).
The OAS hypothesis was first described as “the imprint established by the original virus
infection governs the antibody response thereafter” 40, whereby memory B cells from the primary
5

infection are activated during subsequent infections. When antigenic determinants vary between
strains, these memory B cells can often bind only weakly and provide poor protection to the
second infection. Yet by virtue of reduced activation requirements, these ineffective recall
responses dominate over primary naïve B cells. For DENV, OAS was first described after
observations that while serum antibodies had varying degrees of neutralizing activity to all four
DENV serotypes after heterotypic DENV infection, potent neutralization only occurred to the
primary infecting serotype 41. Similar observations have since been made for memory T cells 42.
Given the overlap in the geographical prevalence of many flaviviruses, increases in travel, and a
potentially exacerbated immune response to secondary infections, there is a need for
understanding recall responses to heterologous flavivirus infections. To understand why nonprotective antibodies dominate secondary responses, we must first discuss the different antibody
epitopes in flavivirus infections.
1.1.a Non-protective and protective antibodies in response to flavivirus infections
Most flavivirus antibodies target epitopes found on the envelope (E) protein, which
mediates cellular attachment and membrane fusion to the host cell

43

. The E protein contains

three different domains (DI to DIII) with both non-protective and protective epitopes

44

. The

primary, non-protective epitope on the E protein is the DII fusion loop (DII-FL), which is highlyconserved across flavivirus species

45, 46, 47

. In humans, this is the immunodominant epitope 46,

and explains why antibodies from one flavivirus infection can cross-react with other flaviviruses
that have yet to be encountered
neutralizing.

48

. In addition, these DII-FL antibodies are frequently poorly-

For many other types of infections, the presence of such non-neutralizing

antibodies is at worst harmless, and at best protective due to engagement of alternate antibody
effector mechanisms such as complement deposition and opsonization. Yet ADE renders such
6

antibodies pathogenic in acute secondary flavivirus infections

37

. How these non-protective

epitopes impact the cellular response in secondary infections is discussed next.
As mentioned above, in humans, antibodies generated during primary infections are
mostly directed against DII-FL, and have poor neutralization ability 46. During acute secondary
infections with a different DENV serotype, plasmablasts secrete cross-reactive, E-specific
antibodies with varying degrees of ADE

49, 50

. These antibodies carry high levels of mutations,

suggesting that they originate from memory B cells. Memory B cells established after primary
and secondary infections appear to retain a greater breadth of antigen specificities (E, prM, and
complex epitopes) than do the responding plasmablasts (predominately E)

51, 52

.

Thus, only a

subset of memory B cells differentiates into antibody secreting cells, where the majority of
antibodies are poorly neutralizing with high ADE activity. Similar findings were observed
following ZIKV infection of DENV-immune patients

53, 54, 55, 56, 57

. Vaccines to protect against

flavivirus infections have thus far revealed similar problems. A licensed tetravalent Dengue
vaccine, CYD-TDV, can mount a neutralizing response to all four DENV serotypes

58

.

However, a longitudinal study on the efficacy of CYD-TDV found an increased risk of severe
disease in previously unexposed individuals compared to those who had previously been exposed
to at least one DENV serotype through natural infection

59

. Thus, CDY-TDV likely promotes

ADE upon natural secondary DENV infection, at least in a subset of individuals who were naive
prior to vaccination. These findings demonstrate the importance of engaging B cells with
strongly neutralizing specificities while avoiding those that preferentially enhance infection.
While non-protective epitopes dominate the human antibody response, mouse studies
have provided critical insight on protective epitopes that can potentially be targeted selectively.
For example, mouse studies have shown that B cell responses are critical for protection against
7

flavivirus infections 2. Passive transfer of minute quantities of immune serum from WNVconvalescent mice into B-cell deficient animals confers protection to homologous virus infection
2

. Analysis of mouse monoclonal antibodies has revealed that the most potent neutralizing

epitopes are located on the lateral ridge epitope of DIII (DIII-LR)

45, 60, 61, 62, 63

. Interestingly,

these DIII-LR specific antibodies are immunodominant in mice, whereas in humans these
specificities clearly exist but are overwhelmed by DII-FL-reactive cells and antibodies 38, 45, 46, 64.
The DIII-LR epitope is only weakly conserved across flavivirus species, and thus, long-lived
plasma cell DIII-LR responses provide type-specific immunity with minimal ability to promote
ADE

61, 63

. Another protective and highly neutralizing epitope is the recently described E dimer

epitope (EDE), present in both DENV and ZIKV 65, 66. Analysis of anti-EDE antibodies isolated
from DENV-infected humans found that these antibodies potently and broadly neutralized all
four DENV serotypes and ZIKV 53, 65, 66. This epitope is present on intact, mature virions but not
on recombinant E, indicating that a quaternary structure is required for antibody recognition.
Because of the complexity of this epitope, an equally complex strategy will likely be required to
selectively generate EDE-specific antibody responses.
1.1.1b Diversity of memory B cells and their reactivation in secondary challenges
Interestingly, mouse studies on WNV infections and vaccinations have demonstrated a
greater diversity of DIII antigenic specificities in memory B cells than in long-lived plasma cells
16

. This fundamental difference in repertoires between memory B cells and constituent serum

antibodies has also been found in humans following a range of different vaccines

15

. The

diversity of WNV-reactive memory B cells imparts them with the ability to cross-react to JEV
DIII upon secondary challenges

16

. These data suggest an ability of DIII-specific memory B

cells, but not pre-existing long-lived plasma cells, to recognize DIII-LR of related flaviviruses
8

upon secondary exposures. This could lead to potent cross-neutralizing responses if these
memory B cells were to be selectively engaged. Several innovative potential solutions are
possible. For example, Richner et al. used a modified RNA to express replication-incompetent
ZIKV subviral particles carrying a mutation in the non-neutralizing DII-FL epitope

67

.

Mice

challenged with this modified RNA were resistant to subsequent DENV2 challenge, whereas
animals immunized with wild-type ZIKV subviral particles w-ere highly susceptible to
heterologous infections. A second potential approach involves the use of DIII subunit vaccines.
Multivalent or sequential DIII-based vaccines could potentially be given to specifically elicit
DIII-LR neutralizing antibodies, either from naïve B cells or pre-existing memory B cells in
subjects that are already immune to at least one flavivirus strain. In seropositive individuals,
responses to heterologous DIII-LR epitopes would require clonal expansion and plasma cell
differentiation of pre-existing cross-reactive DIII-LR-specific IgG+ memory B cells (Figure 1).
Alternatively, engagement of IgM+ memory B cells specific for DIII-LR of one strain could reinitiate germinal centers to affinity mature towards DIII-LR of the new strain (Figure 1). A reallife example where cross-reactive DIII-LR-specific antibodies were expanded in secondary
infections involved ZIKV infection in DENV1-experienced individuals

56

. DENV1 and ZIKV

share two critical amino acids in DIII, and thus memory B cells recognizing this epitope were
selectively expanded. Tapping the potential of pre-existing DIII-LR memory B cells may guide
the best vaccination strategy to elicit potently neutralizing antibodies. Yet different
considerations will need to be employed for vaccines that fail not because of their epitope
specificity, but rather due to the lack of durable immunity elicited, as has been observed in
malaria.

9

1.2 Durability of plasma cell survival and antibody responses--the Achilles heel of malaria
vaccines
Malaria is caused by the Plasmodium parasite, and the P. falciparum species is the
leading cause of death and disease in many developing countries, particularly in Africa 68. Over
half of the world’s population is at risk for malaria, where over 200 million cases of clinical
malaria occur each year
year

68

68

. In addition, over 400,000 deaths, primarily in children, occur each

. Protection against re-infection depends on the presence of long-lasting, neutralizing

serum antibodies

69

as passive transfer of immune serum into actively infected individuals

results in rapid recovery

70

.

However, Plasmodium infections themselves do not reliably

generate durable antibody responses 71; not only are antibodies inefficiently generated, they are
lost in the absence of consistent repeated exposure

72

. Given the high infection and mortality

rate, especially in sub-Saharan African children, development of a highly effective vaccine is of
utmost importance, but the provision of durable immunity poses a major challenge as described
more below.
The most advanced approach is the RTS,S subunit vaccine containing the
circumsporozoite protein (CSP). Preliminary studies revealed that vaccination in malaria-naive
adults yielded robust antibody responses in which 86% were protected from subsequent
Plasmodium challenge

73

. Though CSP-specific antibody titers gradually waned, these initial

findings showed promise for a realistic and scalable vaccine against malaria. However, a study
analyzing vaccine efficacy in the field found that only 34% of Plasmodium partially-immune
Gambian adults given the vaccine were protected from the first round of natural infection

74

.

Within 6 months post-RTS,S vaccination, both antibody titers and epidemiological protection
waned to negligible levels

75, 76

. Though difficult to conclude with certainty without a side-by10

side comparison, these data suggest that the ability of Plasmodium-naive individuals to mount
and maintain a protective response after vaccination is higher than that of Plasmodiumexperienced individuals. These findings further suggest that natural Plasmodium exposures may
alter the ability of B cells to respond, either directly or indirectly. Alternatively, a response
against CSP may intrinsically be short-lived (discussed below). Several elegant studies have
followed the B cell response over time in malaria-endemic areas, and have provided intriguing
clues as to the source of the dysfunction.
1.2.a Atypical memory B cells in Plasmodium infected individuals
Repeated exposures to Plasmodium over the course of multiple wet seasons lead to a
progressive increase in antibodies, but this protective humoral immunity rapidly fades during dry
seasons as the mosquito population diminishes

77

. There is also a progressive increase in the

frequency of atypical memory B cells, balanced by a relative decrease in classical memory B
cells

32, 78, 79

. These atypical memory B cells might be the key to understanding why antibody

responses are so transient following vaccination or repeated natural infections

32

. Originally

identified in HIV patients by expression of the inhibitory receptor FcRH4, these cells fail to
proliferate in response to BCR ligation 29, 80. Moreover, studies of the mouse age-related memory
B cells, the potential analog to human atypical memory B cells, have shown markedly elevated
expression of the transcription factor Zbtb32

81

. This factor suppresses the duration of plasma

cell survival following memory B cell recall responses 82. Thus, it might be that recall responses
mounted by atypical memory B cells are inherently transient.
There remain some conflicting findings regarding the biological properties of atypical
memory B cells. For example, analysis of a relatively small number of cells suggested that
atypical and classical memory B cells were clonally unrelated in Plasmodium-immune
11

individuals83 whereas another larger study found these two cell types to possess overlapping
immunoglobulin repertoires

80

. Some studies observed Ig secretion by atypical memory B cells

both in vivo and ex vivo 83, while others have found these cells to be completely unresponsive to
stimuli

80

. A recent study by Pérez-Mazliah et al. analyzed the MSP1-specific memory B cell

compartment following Plasmodium infection and found that atypical memory B cells were
short-lived and had activated B cell and plasmablast gene signatures 84. Mouse studies have not
resolved these issues, as age-associated memory B cells can readily respond to Toll-like receptor
stimulation

85, 86

, whereas in some studies, human atypical memory B cells do not

87

. Clearly,

additional studies must be performed to explain the differences in these sets of studies. This in
turn will help define whether these cells should be intentionally avoided in vaccine strategies, or
whether they can be safely ignored.
A second finding that may impact the transience of immunity is the emergence of an
unusual T follicular helper (Tfh) cell phenotype. Mouse studies have shown that a proinflammatory environment promotes T-bet expression in pre-Tfh cells, which skews toward a
Th1-like phenotype

79

. Similarly, human circulating Tfh-like cells from Plasmodium-immune

individuals are poised to secrete interferon gamma (IFN- ) and promote T-bet expression in
atypical memory B cells

79, 88

. The high levels of T-bet expression in atypical memory B cells

are associated with decreased BCR signaling and a switch from IgG1 to IgG3 surface expression
88

. In some cases, T-bet expression limits the ability of B cells to differentiate into germinal

center B cells, and ultimately results in reduced IgG antibody titers

89

, though in other cases it

appears that Tbet expression actually enhances serum IgG2c levels 24, 90. Thus, severe malaria is
associated with an inflammatory environment that results in a defective adaptive immune
response. However, for those that recover from severe malaria, Th1-skewed Tfh cells drive the
12

gradual acquisition of T-bet that is eventually enriched in the atypical memory B cell
compartment

79, 88

. Thus, T-bet expression may result in impaired recall responses through its

effects on atypical memory B cells.
1.2.b Alternatives in mounting a durable anti-Plasmodium antibody response
Based on the evidence provided above, there are several aspects to consider to develop a
successful vaccine that provides durable immunity to malaria. First, the outcome of the immune
response changes greatly with exposures. Thus, developing vaccines by testing on naive Western
populations may not be fully predictive of the response in malaria-endemic areas

87, 91

. Along

these lines, it may become necessary to either productively engage atypical memory B cells to
'awaken' them to produce long-lived plasma cells, or to avoid them entirely and target the
classical memory populations instead (Figure 2). This latter strategy would depend on the
existence of at least some non-overlapping antigen specificities between atypical and classical
memory B cells. How best to awaken atypical memory B cells is far from clear, but engagement
of certain pattern- or danger-associate molecular patterns might still be possible. Our own work
has demonstrated that Zbtb32, which is highly expressed by age-associate memory B cells,
restrains the duration of antibody production after recall responses to some challenges, such as
murine cytomegalovirus and alum-adjuvanted immunogens 92. In contrast, Zbtb32 has no role in
controlling recall responses to intestinal bacteria, influenza booster vaccinations, or Ribiadjuvanted immunogens

92

. Thus, selection of proper adjuvants and innate stimuli can greatly

influence the survival program engaged by plasma cells and the duration of immunity 93, 94.
A second, and potentially more problematic scenario, is that inherent constraints within
the human germline repertoire or pathogen evasion mechanisms prevent durable responses to
certain Plasmodium antigens. Although the RTS,S vaccine response was more effective in
13

malaria-naïve individuals than in malaria-experienced subjects, antibody responses still faded
quite rapidly relative to a number of more robust vaccines and infections

95, 96

. To define the

underlying cause to these problems, a recent mouse study demonstrated that blood-stage
parasites actively suppress the response to CSP

97

. Other animal studies using different

immunization and infection models have demonstrated that both the avidity of the antigen for its
target BCR as well as the self-reactivity of the starting naïve B cell can greatly influence the
duration of immunity. Studies using the model antigens demonstrated that when the starting
avidity of the antigen is very high, paradoxically the duration of IgG memory B cell persistence
is diminished 98. Additionally, high model antigen avidity promotes the expansion of short-lived
plasma cells 99, 100. Yet in the context of HIV infection, a minimum antigen affinity is essential to
effectively recruit pathogen-specific B cells into the response 101. Thus, it may be that an antigen
avidity 'sweet spot' is required to generate the ideal durable response to Plasmodium. Adding to
this complication is that some foreign antigen-specific B cells are also somewhat self-reactive,
thereby diminishing their contribution to or durability following the response 102, 103, 104, 105. These
problems can begin to be addressed by empirical antigen redesign and experimental animal
studies. For example, although blood stage infection inhibits responses to CSP, responses to
merozoite surface protein 1 remain intact and protect mice from subsequent infection 97, 106.
Targeting naive B cells of very rare specificities may be an alternate but effective
strategy. For instance, while antibody responses to the four amino acid (NANP) repeats of CSP
increase over time post-infection, this is not due to increases in affinity maturation within the
germinal center. Instead, recruitment of naïve B cells with higher affinity than responding
memory B cells drives these increases, as somatic hypermutations are often not affinityenhancing

107

.

In addition, a surprising study isolated RIFIN-binding, broadly-reactive
14

antibodies that recognize multiple P. falciparum isolates

108

. These highly unusual antibodies

have inserted the collagen binding domain of LAIR1, an Ig superfamily inhibitory receptor,
between the V and DJ segments. Somatic mutations in the LAIR1 domain abolished binding to
collagen and increased binding and opsonization of infected erythrocytes. These broadly reactive
antibodies were isolated from IgG+ Memory B cells, and found to be highly clonally expanded
in the two donors studied. Thus, targeting high affinity naïve B cells may be a way to avoid
atypical memory B cells and produce durable immunity.
There are still many outstanding questions on the association and causation between
malaria severity and atypical memory B cells. Longitudinal studies analyzing the repertoire of,
and clonality between, the memory B cell and plasmablast compartments after each malaria
season will be important for understanding the development and contribution of atypical memory
B cells. Are atypical memory B cells originally classical memory B cells that have been
exhausted or are they a separate fate during germinal center reactions? Given that naturally
acquired immunity is associated with an expanded atypical memory B cell pool, what is the
association between protection and atypical memory B cells? In addition, there appears to be
different subsets of atypical memory B cells based on T-bet expression and/or isotype
expression. Do the functions of these different subsets differ in recall response? In this case,
malaria is a good infection system to use to study different aspects of atypical memory B cell
biology.
1.3 Conclusion
Decades of research in model organisms have defined the basic and essential elements of
cellular and humoral immunity. Increasingly sophisticated analysis in the field has revealed
properties of human responses to problematic infections, which in turn has driven a progression
15

of mouse models that accurately mimic these issues 109. Of course not all aspects of responses are
identical between humans and mice, but our viewpoint is that evolution likely preserves the most
fundamental aspects of antibody responses. Even in the cases where there are differences
between mice and humans, such as in the immunodominant antigens after flavivirus infection,
mouse studies have revealed critical neutralizing epitopes that may form the basis for new human
vaccines. As increasing numbers of reports define new structure-based methods to elicit epitopespecific antibodies, basic studies will help guide these specificities into the correct cellular
compartments to provide robust and durable humoral immunity.
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Figure 1.1 Actual and ideal responses to heterologous flavivirus infections.
Secondary flavivirus infections in humans can result in pathogenic responses, where the
immunodominant epitope is the highly conserved fusion loop on the envelope protein domain II
(DII-FL). Non-neutralizing DII-FL antibodies facilitate increased viral load through a process
called antibody-dependent enhancement (ADE). Ideally, the response to heterologous challenge
should result in the expansion of protective antibodies and memory B cells. This can either be
achieved by recruiting DIII-LR cross-reactive IgM+CD80-PD-L2- memory B cells into the
germinal center (GC) response to affinity mature towards the new heterologous DIII-LR epitope,
or by differentiating pre-existing cross-reactive DIII-LR specific IgM+CD80+PD-L2+ memory B
cells into long-lived plasma cells (LLPCs).
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Figure 1.2 Actual and ideal response to Plasmodium.
Plasmodium infections in humans result in expanded, hyporesponsive atypical memory B cells
(aMBCs), contracted classical memory B cells (cMBCs), and short-lived antibody responses.
Each additional infection by Plasmodium results in further increases in aMBCs and short-lived
plasma cells (SLPCs). Therefore, multiple infections are needed for immunity. Given this
challenge, vaccines need to be carefully designed to induce long-lived plasma cells (LLPCs) for
a robust and durable response. To mount a robust and durable response, either adjuvants that can
render aMBCs responsive must be used, or memory B cells that can recognize epitopes that
confer durable and protective responses must be selectively activated and expanded.

26

Chapter 2:
Affinity-restricted memory B cells dominate recall responses to
heterologous flaviviruses.

This work was performed in collaboration with Jennifer Govero, Jennifer Uhrlaub, Haiyan Zhao,
John M. Errico, Lucas D’Souza, Tyler J. Ripperger, Janko Nikolich-Zugich, Mark J. Shlomchik,
Daved H. Fremont, Michael S. Diamond, and Deepta Bhattacharya. Personal contributions
include the design and carrying out of selected experiments, data analysis, and writing of this
work.
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2.1 Abstract
Memory B cells (MBCs) can respond to heterologous antigens either by molding new
specificities through secondary germinal centers (GCs) or by selecting pre-existing clones
without further affinity maturation. To distinguish these mechanisms in flavivirus infections and
immunizations, we studied recall responses to lateral ridge epitopes, which are potently
neutralizing but poorly conserved across species. Conditional deletion of activation induced
cytidine deaminase (AID) between heterologous challenges of West Nile, Japanese encephalitis,
Zika, and Dengue viruses did not affect the quality and quantity of recall responses. DIII-LRspecific MBCs were contained mostly within the plasma cell-biased CD80+ subset and few GCs
arose following heterologous booster vaccinations, demonstrating that recall responses are
confined by pre-existing clonal diversity. Measurement of monoclonal antibody binding affinity
to DIII proteins, timed AID deletion, single cell RNA-sequencing, and lineage tracing
experiments suggest continuous commitment of relatively low affinity MBCs in the first weeks
of the GC as a mechanism to promote diversity. Restricting this diversity through immunogen
design may allow for generation of type-specific vaccines with little potential for infection
enhancement of heterologous flaviviruses.
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2.2 Introduction
After clearance of infections or vaccines, long-lived plasma cells (LLPCs) and memory B
cells (MBCs) persist to maintain durable humoral immunity. While MBCs proliferate and
differentiate into effector lineages upon antigen re-exposure, LLPCs constitutively secrete
antibodies irrespective of the presence of antigen and can provide sterilizing immunity against
subsequent homologous or closely related infections

1, 2

. Because of these properties, LLPC-

derived circulating antibodies can also sequester antigen that would otherwise activate MBCs 3, 4.
From an evolutionary standpoint, it seems unlikely that MBCs serve solely as an adjunct to
LLPCs to bind excess antigen, since physiological inocula are often comprised of only a small
number of infectious microbes 5. Instead, the most important role of MBCs may be to respond to
pathogens that have antigenically changed since the first exposure, thereby evading pre-existing
serum antibodies. Hapten-specific MBCs have fewer affinity-enhancing mutations than do
LLPCs

6, 7

,

providing evidence that the repertoires of these two cell types do not fully overlap.

Subsequent work demonstrated that pathogen-specific MBCs have distinct repertoires and
distributions of epitope specificities relative to LLPCs 8, 9, 10. These findings led us and others to
propose that the diversity of MBCs enables them to combat escape mutants and heterologous
viruses better than do LLPCs 10, 11, 12.
In theory, MBCs can respond to heterologous pathogens or escape mutants in two ways.
First, the diversity of this compartment may be sufficient to allow the clonal selection of crossreactive MBCs without additional affinity maturation. Second, MBCs might re-initiate germinal
centers (GCs) to shape new B cell receptors (BCRs) tailored to the second heterologous
challenge. This decision is mediated principally by the subset of responding MBCs. In mice,
MBC subsets can be defined by their surface expression of CD80 and programmed cell death 1
29

protein ligand 2 (PD-L2). CD80+PD-L2+ MBCs preferentially differentiate into plasma cells
upon antigen re-challenge, whereas MBCs lacking CD80 and PD-L2 expression differentiate into
GC B cells

13

. Though causally unrelated to isotype

13, 14, 15, 16

, these subsets partially correlate

with IgG versus IgM expression. CD80+PD-L2+ MBCs are enriched for IgG expression, while
CD80-PD-L2- cells tend to express IgM. Accordingly, both in mice and humans, IgG+ MBCs
preferentially differentiate into plasma cells after re-challenge, whereas IgM+ MBCs re-initiate
GC reactions

3, 17, 18

. While adoptive transfer, ex vivo culture, and transcriptional profiling

experiments have established the differentiation potentials of these MBC subsets in isolation, it is
challenging to define how these subsets act in concert and competition with one another in vivo,
where serum antibodies and memory CD4+ T cells may modulate recall responses to
heterologous antigenic challenges. Mouse studies using model antigens have reached differing
conclusions on how efficiently MBCs re-initiate GCs and undergo secondary affinity maturation,
as have human influenza studies

3, 14, 19, 20, 21

. Resolving these differences experimentally is

challenging, as there have been no reports of genetic tools that can distinguish the functional
importance of secondary GC reactions versus clonal selection of pre-existing diversity without
also altering other components of the immune response.
Flaviviruses represent a particularly relevant system to differentiate between these
possibilities. Pathogenic flaviviruses, such as West Nile (WNV), Japanese encephalitis (JEV),
Dengue (DENV), and Zika (ZIKV) viruses co-circulate in similar geographic regions. Although
primary flavivirus infections result in durable homotypic protection

22

, in some instances,

subsequent infections by heterologous flaviviruses can result in more severe symptoms than if
the host were naïve 23, 24. The increased severity of heterologous secondary infections is mediated
in part by antibody dependent enhancement (ADE), and is a contributing factor as to why safe
30

and effective vaccines for DENV have been challenging to develop. ADE is a process by which
poorly or non-neutralizing antibodies generated after the first infection enhance uptake of the
second heterologous virus in mononuclear phagocytes via Fcg receptors 25, 26, 27.
The majority of flavivirus antibodies recognize epitopes on the envelope (E) protein

28

.

The E protein is divided structurally into three domains (DI, DII, and DIII) 29. DII contains an
immunodominant fusion loop (DII-FL) epitope that is recognized by poorly neutralizing
antibodies and is conserved across flavivirus species

30, 31, 32, 33, 34

. Antibodies that bind to the

DII-FL epitope can thus recognize multiple flaviviruses and potentially mediate ADE. In
contrast, DIII contains the lateral ridge (DIII-LR) epitope, which is recognized generally by
flavivirus type-specific neutralizing antibodies 30, 35, 36, 37, 38, 39. Potently inhibitory antibodies that
bind the DIII-LR epitope neutralize at a post-attachment step by preventing E protein dimertrimer transitions necessary for viral fusion

36

, and protect against West Nile (WNV), Japanese

encephalitis (JEV), Zika (ZIKV), and Dengue (DENV) virus infections in vivo. Because of these
data, the DIII-LR epitope is an attractive candidate for vaccine immunogen design.
The DIII-LR epitope is less well-conserved at the sequence level across different
flavivirus species. Therefore, resultant antibody responses are less cross-reactive and do not
appear to cause ADE

40, 41

. DIII-LR monoclonal antibodies (mAbs) that cross-react between

DENV and ZIKV have been observed, but these antibodies are rare despite their evolution from
a ‘public’ germline lineage 42, 43, 44. Notwithstanding this, it remains unknown whether polyclonal
MBCs generated after one flavivirus vaccination or infection respond to the DIII-LR epitope of a
subsequent heterologous vaccination or infection. If pre-existing MBCs could be used as a
template for new specificities through secondary GCs, this would rationalize a strategy of
sequential heterotypic DIII-LR immunizations in geographic areas in which large fractions of
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individuals are already immune to at least one endemic flavivirus

45

. In contrast, if recall

responses were dominated by MBCs with little capacity to re-initiate new GCs, this might lead to
weakly cross-neutralizing antibodies that could promote ‘original antigenic sin’ and ADE when
faced with virus infections

23, 46, 47

. In this latter case, immunogen design is warranted to avoid

pre-existing MBCs and antibodies to minimize cross-reactivity and promote virus type-specific
responses.
To differentiate between these possibilities, we generated mice in which activationinduced cytidine deaminase (AID), which mediates both class switching and somatic
hypermutation 48, can be temporally deleted prior to the recall response. The lack of AID would
prevent subsequent diversification or redirection of BCR specificity towards a heterologous
antigenic target in secondary GCs.

Nonetheless, AID deletion minimally impacted recall

responses against heterologous flavivirus antigen epitopes, suggesting clonal selection from a
diversity of pre-existing MBC specificities with little role for further secondary affinity
maturation towards heterologous antigens. This diversity is promoted by the selection of low
affinity antigen-specific B cells that are continuously recruited into the MBC compartment.
Restricting the initial diversity through immunogen design may allow for flavivirus type-specific
vaccines with minimized potential for infection enhancement.
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2.3 Results
MBCs do not require additional affinity maturation to respond to heterologous challenges.
We previously demonstrated that MBCs are capable of recognizing a WNV mutant
selected to escape neutralizing antibodies

10, 49

. This mutation attenuates WNV infectivity and

does not occur naturally. Thus, the mechanisms by which MBCs recognize neutralizing epitopes
on naturally-occurring heterologous flaviviruses remains unexplored. To address this issue, we
first developed a mouse model that allows for temporal abrogation of somatic hypermutation,
and thus further affinity maturation, between primary and secondary challenges. Mice were
generated with loxP sites flanking exon 2 of the Aicda gene (Figure 2.1A-B). Aicda encodes
activation induced cytidine deaminase (AID), a protein that is critical for class switching and
somatic hypermutation

48

. These mice allow us to distinguish the contributions of secondary

affinity maturation of MBCs versus clonal selection of MBCs with pre-existing specificities, as
the former requires expression of AID whereas the latter does not.
Aicdaf/f mice were crossed to a tamoxifen-inducible, hCD20-B cell specific Cre
recombinase (TamCre) 50 (Figure 2.1A). To confirm deletion of AID at the protein level, Aicdaf/f
x TamCre (AID cKO) mice were immunized with sheep red blood cells, treated with tamoxifen,
and then GC B cells sorted at different time points after tamoxifen treatment. AID protein
expression was abolished rapidly after tamoxifen treatment and remained undetectable by
immunoblot for at least seven days (Figure 2.1C). To confirm loss of class switching after AID
deletion, AID cKO and Aicdaf/f (AID WT) mice were treated with tamoxifen for two weeks,
vaccinated against WNV using an inactivated veterinary vaccine, which generates similar
antibody responses and specificities as do live infections 10, and IgG responses were assessed 12
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days later (Figure 2.1D). As expected, AID cKO mice failed to mount an isotype-switched IgG
response to WNV DIII (Figure 2.1D).
We next established a heterologous flavivirus immunization system to specifically
monitor recall, but not primary antibody responses. WNV and JEV are related flaviviruses in the
same serogroup and have DIII amino acid sequence similarity of approximately 75%. We thus
employed Ixiaro, an alum-adjuvanted, clinically approved, inactivated JEV vaccine, which
requires multiple immunizations to elicit a protective antibody response

51

. Naïve mice

challenged with Ixiaro generated few detectable JEV DIII-specific antibodies (Figure 2.2A). In
contrast, JEV vaccination of WNV-immune mice resulted in an increase in JEV DIII-specific
serum antibodies (Figure 2.2A).

Thus, JEV-DIII antibodies can be elicited efficiently in

secondary heterologous recall responses.
The importance of secondary affinity maturation of MBCs was determined by deleting
Aicda between WNV and JEV challenges. AID WT and AID cKO mice were vaccinated with
WNV and the primary response was allowed to proceed. Mice then were treated with tamoxifen
56 days later to delete AID, and then re-vaccinated with JEV (Figure 2.2B). Serum antibody
titers to WNV and JEV DIII proteins were then quantified by ELISA. We also monitored
responses to recombinant DIII proteins carrying point mutations that ablate the LR epitope and
abolish binding by potently neutralizing mAbs. For WNV DIII, we incorporated K307E and
T330I mutations (KT DIII)

35, 36

, whereas for JEV DIII we introduced 4 LR mutations

(E306A/S329I/A366E/K390S, JEV ESAK-DIII)

based on previously solved structures

52

.

Proper reactivity and refolding of the JEV ESAK-DIII protein was confirmed by ELISA using
the LR-specific neutralizing mAb JEV-31

37

, and serum from immunized mice (Figure 2.3A).

Thus, antibodies that bind WT DIII but not mutant DIII are considered DIII-LR-specific. Most
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antibodies that bind both WT DIII and mutant DIII likely recognize a distinct non-LR DIII
epitope, though a minority may remain DIII-LR-specific and tolerate the mutations.
Deletion of AID prior to JEV booster vaccination had no discernible effect on serum IgG
or IgM titers against WNV WT DIII, WNV KT DIII, JEV WT DIII, or JEV ESAK DIII between
days 14-70 of the recall response (Figure 2.2C, Figure 2.3B-C). Recall responses were
primarily directed against non-LR epitopes, as most antigen-specific antibodies bound WNV KT
DIII and JEV ESAK DIII (Figure 2.2C). However, the levels of JEV WT DIII-reactive
antibodies were higher than those against JEV ESAK DIII (Figure 2.2D). These data suggest
that although most of the response is accounted for by WNV-JEV cross-reactive non-LR
antibodies, a subset of the MBC response is directed against the neutralizing DIII-LR epitopes of
both WNV and JEV. These responses were not affected by AID deletion (Figure 2.2D).
Accordingly, deletion of AID also did not alter the serum neutralization response to JEV (Figure
2.2E). These data demonstrate that rare pre-existing MBCs mediate cross-neutralizing responses
without a requirement for further somatic hypermutation and affinity maturation upon
heterologous flavivirus challenges.
We considered the possibility that additional affinity maturation is necessary for more
disparate heterologous challenges. ZIKV, another member of the flavivirus genus, shares ~ 55%
DIII amino acid sequence similarity with JEV. We tetramerized recombinant ZIKV DIII to
improve avidity, immunized mice, and then followed with JEV vaccination (Figure 2.2F).
Deletion of AID prior to JEV booster vaccination in ZIKV DIII-immune mice did not impact
IgG or IgM antibodies against ZIKV DIII, JEV DIII, JEV ESAK DIII, or LR-mutant ZIKV DIII
(ZIKV AT DIII 38) (Figure 2.2G, Figure 2.3D-E). To determine if secondary affinity maturation
occurs following heterologous infections, rather than vaccinations, we utilized a sequential
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DENV and ZIKV infection model (Figure 2.3F). DENV2 and ZIKV DIII share approximately
46% amino acid similarity. Analysis of ZIKV DIII-specific MBCs and LLPCs, after correcting
for naïve B cell responses against ZIKV, again suggested a minimal role for secondary GC
reactions and affinity maturation (Figure 2.3G). These data demonstrate that for responses
against both similar and disparate flavivirus DIII-LR antigens, for both vaccines and infections,
secondary affinity maturation is minimally involved. Instead, heterologous challenges promote
clonal selection from pre-existing cross-reactive MBCs expressing neutralizing antibodies.

Plasma cell-biased MBCs recognize and respond to heterologous antigens.
We next sought to define a cellular mechanism as to why secondary affinity maturation
was not engaged in heterologous recall responses. The decision to initiate new GCs or plasma
cells is largely determined by the responding MBC subsets, which are distinguished using a
combination of IgM, IgD, CD80, CCR6, PD-L2, and CD73 as markers (Figure 2.4)

15, 17, 53, 54

.

PD-L2 and CD73 expression largely overlapped with CCR6 irrespective of immunoglobulin
isotype (data not shown), suggesting redundancy between these markers. Thus, we focused
subsequent analyses on CCR6 and CD80 expression. Antigen-specific MBCs in WNVvaccinated mice were identified using bacterially-expressed site-specifically biotinylated
recombinant DIII assembled into tetramers with streptavidin-fluorophore conjugates (Figure
2.4). Only the isotype-switched (swIg, IgM-IgD-) CD80+CCR6+ MBC subset was enriched for
WNV DIII-specificity in vaccinated mice relative to unimmunized animals (Figure 2.5A).
These CD80+ MBCs preferentially generate plasma cells upon re-encounter with cognate antigen
13

.
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Secondary affinity maturation plays a minimal role in recall responses to JEV, suggesting
the existence of WNV-JEV cross-reactive MBCs prior to Ixiaro vaccination. Indeed, after
primary vaccination with WNV, nearly half of WNV KT DIII-reactive MBCs recognized both
JEV DIII-WT and JEV ESAK DIII (Figure 2.5B). These cells likely cross-react with conserved
non-LR epitopes between DIII of WNV and JEV. In contrast, only ~1% of WNV DIII-LRspecific MBCs also bound JEV DIII (Figure 2.5B). These data are consistent with previous
studies reporting rare but detectable DIII-LR monoclonal antibodies that cross-react with
different flavivirus species

37, 42, 43, 44

. These data are also consistent with Figure 2.2D, in which

the majority, but not all, of the response is directed against conserved DIII non-LR epitopes.
Indeed, JEV vaccination of WNV-immune mice as in Figure 2.2A led a marked increase in
WNV KT DIII-reactive antibodies (Figure 2.5C). Yet we detected only a very small frequency
of WNV-DIII-specific GC B cells following JEV vaccination of WNV-immune mice (Figure
2.5D), consistent with our observations that antigen-specific MBCs are mostly contained within
the CD80+ plasma cell-biased subset (Figure 2.5A). These data suggest a minimal role for
secondary GCs in recall responses to heterologous neutralizing DIII-LR epitopes. Instead, recall
responses are dominated by pre-existing cross-reactive MBCs.

MBCs are actively selected from GC B cells.
Our data demonstrate that recall responses to heterologous flaviviruses in mice are
restricted by the pre-existing MBC diversity, with little capacity to shape new specificities
through secondary GCs. We therefore sought to define mechanisms by which this MBC diversity
is generated during the primary response. Given the results above, we focused on mechanisms by
which CD80+ MBCs are selected from GCs. Diversification can be achieved potentially through
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random selection of GC B cells into the MBC compartment

55

. This would result in similar

distributions of antigen-specificities in both GC and MBC compartments. However, if active
selection occurred, the antigen-specificity distributions between MBCs and GC B cells might
differ.
To distinguish these possibilities, wild-type mice were vaccinated against WNV and the
DIII specificities in the GC B cell and MBC compartments were quantified by flow cytometry at
different time points. GC B cells (CD19+GL7+CD38-IgD-) showed a skewed frequency of WNV
DIII-reactive cells towards the LR epitope, although a small fraction of non-LR specific cells
was present at stable frequencies throughout the experiment (Figure 2.6A). In contrast, MBCs
were far less skewed towards the WNV DIII-LR epitope (Figure 2.6B), consistent with previous
findings

10

. The durable MBC population at late timepoints post-vaccination more closely

mirrored the WNV DIII-LR and DIII non-LR frequencies at 1-2 weeks post-immunization than
those at 3-4 weeks (Figure 2.6B). These data are consistent with a relatively early wave of MBC
formation that contributes most of the durable memory population 7, and with the low lifespans
of the highest affinity and somatically mutated MBCs

56, 57

. MBCs had a larger ratio of WNV

DIII non-LR:DIII-LR specificities than did GC B cells at all timepoints analyzed (Figure 2.6C).
To confirm that WNV DIII non-LR specific GC B cells are more predisposed towards the MBC
fate, we analyzed the frequency of CD38+CCR6+ MBC precursor cells for WNV DIII-LR and
WNV DIII non-LR specific GC B cells (CD19+GL7+IgD-). CCR6 and CD38 expression mark
both mature MBCs and GC precursors committed to the MBC fate

53, 58, 59

. In the CD38+CCR6+

MBC precursor population, WNV DIII non-LR-specific cells were detected at greater frequency
than WNV DIII-LR specific cells at all time points analyzed (Figure 2.6D). Thus, although the
frequency of WNV DIII non-LR-specific GC B cells was low, these cells were either
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preferentially selected or maintained within the MBC compartment. The early emergence from
the GC of WNV DIII-specific MBCs, especially those that are DIII non-LR specific, suggests
that these cells likely underwent less affinity maturation and remained of low affinity, implying
mechanisms as to why the MBC compartment is antigenically diverse.

MBCs have lower avidity for their antigens than do LLPCs
In both the hapten-response setting and in our results above, MBCs begin to exit GCs
earlier than do bone marrow plasma cells 7, perhaps resulting in lower overall antibody affinity.
Based on the number of somatic mutations, LLPCs are thought to be selected from high affinity
GC B cells 7, 60, 61, 62, whereas MBCs are thought to be selected from low affinity GC B cells due
to lack of T cell help 63. Thus, it is possible that an avidity threshold determines the MBC versus
LLPC fate decision. A lowered avidity threshold, and therefore increased permissiveness to bind
variant antigens, in turn could promote diversity in the MBC compartment. To determine if
MBCs in our system have lower affinity or avidity for their antigen compared to LLPCs, we
established methods to identify DIII-specific LLPCs and MBCs. Although plasma cells secrete
most of their antibodies, we observed similar expression of surface Igk as by other B cells in the
bone marrow (Figure 2.7A), consistent with previous studies

64

.

We therefore used

recombinant DIII tetramers to stain and sort single antigen-specific LLPCs and MBCs (Figure
2.7A-B), cloned their V(D)J sequences into expression vectors, and then expressed and purified
recombinant monoclonal antibodies (mAbs) 65. The cloned mAbs from MBCs and LLPCs were
specific for WNV DIII as determined by ELISA and biolayer interferometry. Analogous to the
flow cytometry data, more than three times as many mAbs generated from cloned MBCs
recognized WNV DIII non-LR compared to those derived from cloned LLPCs (Table 2.1).
39

We first tested mAbs for their ability to bind monomeric WNV WT DIII. MBC-derived
mAbs bound to monomeric WNV WT DIII similarly as did mAbs from LLPCs, with modest
reductions in binding seen only at the highest concentration of antibody tested (Figure 2.8A).
Reversing the orientation of a subset of the antibodies and WNV WT DIII on the ELISA plate to
test affinity rather than avidity also failed to reveal differences between MBC- and LLPCderived mAbs (Figure 2.7C). To obtain data on binding kinetics of these mAbs, we performed
biolayer interferometry (BLI). Affinities and on-rates again were similar between mAbs derived
from MBCs and LLPCs (Figure 2.8B, Figure 2.7D). If anything, a small reduction in off-rates
was observed in MBC-derived mAbs compared to LLPC-derived mAbs (Figure 2.7D). These
data demonstrate that the B cell receptors (BCRs) of MBCs and of LLPCs bind monomeric DIII
similarly.
Given that WNV E proteins assemble into rafts of dimers on an icosahedral virion 66, we
considered the possibility that LLPC-derived mAbs might bind native viral structures better than
MBC-derived mAbs. To evaluate this, we tested the avidity of the mAbs to WNV subviral
particles (SVPs), which have similar icosahedral structures to fully infectious virions

67, 68

.

LLPC-derived mAbs bound with higher avidity to SVPs than MBC-derived mAbs (Figure
2.8C). This result suggests that an avidity threshold for multimeric flavivirus antigens may
distinguish MBC from LLPC selection in the GC and dictate the repertoire of antigens
recognized.

Absolute affinity thresholds do not segregate MBCs from LLPCs in vivo
Our data are consistent with the existence of either an absolute affinity threshold that
promotes LLPCs and excludes MBCs, or a relative threshold in which the comparatively lowest
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affinity B cells within a given GC are allocated to the MBC compartment, perhaps due to the
differences in the timing of their selection 7. To determine if an absolute affinity threshold
promotes the LLPC fate and results in a diverse MBC compartment in vivo, we utilized our
Aicdaf/f x TamCre mouse model to freeze affinity maturation at different timepoints during the
GC reaction. We first defined timepoints at which AID deletion abrogates affinity maturation but
not class-switch recombination, and during which MBCs were formed but bone marrow plasma
cells had not yet emerged. This is important given differences in IgM and IgG signaling that can
influence plasma cell selection 56, 67, 68, 69, 70, 71, 72. At both 7 and 14 days after WNV vaccination
in wild-type mice, the frequency of WNV DIII-specific GC B cells that had class switched was
high (~90%, Figure 2.9A). This is consistent with recent studies showing that class-switch
recombination occurs prior to GC formation 73. In contrast, the number of somatic mutations in
WNV DIII-specific GC B cells increased each week post-vaccination (Figure 2.9B),
demonstrating ongoing affinity maturation.
To determine the kinetics of accumulation of WNV DIII-specific bone marrow plasma
cells, ELISPOT assays were performed at different time points after vaccination. We found that
WNV DIII-specific bone marrow plasma cells were detectable at 2 weeks post-vaccination and
peaked 1 week later (Figure 2.9C), whereas MBCs emerged earlier (Figure 2.6B). We deleted
AID at 1 or 2 weeks post-WNV vaccination to temporally abrogate affinity maturation and
assessed the impact on MBC and LLPC numbers 8 weeks later (Figure 2.10A). The frequencies
of WNV DIII-LR and DIII non-LR specific MBCs were unaffected by AID deletion at weeks 1
or 2 post-vaccination (Figure 2.10B). Cre expression alone also did not alter antibody responses
to WNV WT DIII or WNV E protein (Figure 2.9D). AID deletion at 1 week after vaccination
led to reduced anti-WNV DIII IgG serum antibody titers and slightly reduced numbers of DIII41

reactive LLPCs relative to control mice (Figure 2.10C, Figure 2.9E). This may indicate an
affinity threshold for plasma cell selection, but these data also could be explained by a reduction
in the affinity of antibodies and resulting inability to detect all antigen-specific LLPCs.
Consistent with the latter mechanism, deletion of AID 2 weeks after WNV vaccination did not
affect serum antibody titers or the number of WNV DIII-specific LLPCs (Figure 2.10C, Figure
2.9E). Moreover, serum antibodies bound equivalently to multivalent WNV SVPs irrespective of
AID deletion (Figure 2.10D). IgM antibody responses against WNV were also unaffected by
AID deletion (Figure 2.9F). Collectively, these data indicate that an in vivo absolute affinity
threshold does not exist below which GC B cells are destined to become MBCs. These data are
consistent with a recent study showing that AID-dependent affinity maturation is dispensable for
LLPC and MBC formation

56

. Notwithstanding this, our data do not exclude the existence of a

relative affinity threshold that segregates MBC and LLPC specificities.

Germline affinities of MBC antibodies are lower than those of LLPCs
Previous studies using model antigens and BCR transgenic mice have demonstrated that
MBCs and LLPCs of the same specificity have different affinities

7, 58, 60, 62, 63

. Yet how

differences in affinity would explain changes in specificities between MBCs and LLPCs in a
polyclonal response is not immediately obvious. We first considered several affinity-independent
mechanisms. One possibility is that distinct B cell subsets, such as marginal zone B cells,
preferentially contribute to the MBC compartment. However, the antigen-specific precursor
frequencies for DIII-LR and DIII non-LR were similar between marginal zone B cells and
follicular B cells (Figure 2.11A). Furthermore, the V, D, and J genes used by our mAbs did not
reveal obvious differences between the MBC and LLPC compartments (Figure 2.11B, Table
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2.1). As repertoires of marginal zone B cells, B1 B cells, and follicular B cells are markedly
distinct

74

, these data argue against a mechanism by which distinct B cell subsets contribute to

MBCs versus LLPCs. A second possibility is that MBCs emerge from precursors that are more
self-reactive than LLPCs. Indeed, in human studies, MBCs tend towards self-reactivity

75, 76

.

However, we observed no changes in the ratios of DIII-LR and DIII non-LR during the transition
from Hardy Fractions E-F (Figure 2.11C), during which self-reactivity is purged 77, 78, 79, 80, 81, 82.
Although WNV DIII-LR cells in Fraction E displayed slightly lower surface levels of IgM, a
marker of anergy and self-reactivity 80, than did WNV DIII non-LR specific cells, these lowered
levels were not maintained in the recirculating mature Fraction F cells (Figure 2.11C). Thus,
these avidity-independent mechanisms fail to explain how MBCs acquire specificities distinct
from their LLPC counterparts.
Another possible explanation is that the starting populations of B cells destined to
become MBCs are distinct from and possess lower avidities than those of LLPC precursors. In
this setting, a diverse set of MBC precursors, including those with weak binding to potentially
poor epitopes such as DIII non-LR, are allowed to participate in the response. Indeed, B cells
with immeasurably low affinities can participate in the response and contribute to MBCs 83, 84, 85,
86

. To test this possibility, we reverted somatic mutations in V(D)J regions from our mAbs back

to their germline sequences and assessed their abilities to bind monomeric WNV WT DIII and
WNV SVPs by ELISA. Germline-reverted MBC-derived mAbs bound more weakly (>10-fold)
to WNV DIII and WNV SVPs than did germline-reverted LLPC-derived mAbs (Figure 2.12A).
These data suggest that MBCs originate from relatively low avidity naïve B cells that are distinct
from those of their LLPC counterparts.

43

Although MBCs have been proposed to be selected for low avidity from GCs 63, this does
not preclude affinity maturation of their precursors. Indeed, mutation analysis of our panel of
monoclonal antibodies indicate that MBCs have similar numbers of replacement mutations in
their V(D)J genes as do LLPCs (Figure 2.12B). MBC clones had in fact slightly greater
numbers of silent mutations than did LLPCs, and the total number of mutations were similar
between MBCs and LLPCs (Figure 2.11D). Polyclonal IgH repertoire analysis during weeks 14 of the response revealed reduced levels of somatic mutations in the MBC compartment relative
to LLPCs, but only at weeks 3-4. For reasons that are unclear, the average number of mutations
in the MBC population decreased somewhat after week 2, and the earlier week 1-2 timepoints
better reflected the ultimate number of mutations observed in mAbs derived from week 8 MBCs
(Figure 2.12B, 2.11E). These data provide further evidence that the durable pool of MBCs is
formed early in the response 7. In both the MBC and LLPC compartments, affinity-matured
antibodies bound better to monomeric WNV DIII than did their germline-reverted counterparts
(Figure 2.12C). The extent of affinity maturation was difficult to calculate precisely, as many
germline-reverted MBC mAbs bound antigen very poorly. A similar degree of affinity
maturation was observed for binding to WNV SVPs (Figure 2.12D). Taken together, these data
demonstrate that although B cells destined to become MBCs may be of low relative affinity, they
still participate in GC reactions and substantially and rapidly improve their ability to bind
antigen.

MBCs are continuously committed from GCs.
MBCs and LLPCs have distinct naïve precursor populations of differing avidities and
specificities, yet how these precursors remain biased toward a given fate throughout the GC is
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unclear. Moreover, the selection of low affinity GC B cells into the MBC compartment is
challenging to reconcile with the marked degree of MBC affinity maturation we observed in
DIII-specific mAbs, resulting in many MBCs with nanomolar BCR affinities (Figure 2.8B). We
considered two explanations for these observations. First, it is possible that B cells become
specified and committed to the MBC fate very early in the response, but still retain GC potential
and transcriptional programs, and thus are allowed to affinity mature. Second, it is possible that
MBC commitment occurs continuously from GCs, which, based on BrdU pulse-chase data,
likely occurs over the first few weeks of the response 7. Thus, as GCs improve their overall
affinities over time, so too does the pool from which MBCs are selected. In this second
mechanism, evidence of early MBC specification would be observed within the main body of
GCs in addition to the fully-committed MBC precursors. To distinguish between these
possibilities, we first performed single cell RNA sequencing of WNV DIII-specific mature GC B
cells, which are marked by EphrinB1 expression (Figure 2.13A)

87

, and examined cells with

both GC and MBC transcriptional signatures.
Uniform Manifold Approximation and Projection (UMAP) analysis of the data revealed
five transcriptional clusters (Figure 2.14A) that segregated independently of cell cycle genes
(Figure 2.13B). Clusters 0, 1, 2, and 4 contained cells expressing Aicda, Bcl6, Jchain, Cxcr4,
Foxo1, and Cd86 and thus represent mature GC B cells with light zone and dark zone signatures
(Figure 2.14B, Figures 2.13C-D). Cluster 3 lacked Aicda expression and instead expressed high
levels of CD38, which marks EphrinB1+ MBC precursors 87. We further confirmed that cluster 3
is enriched in genes associated with MBC commitment (Figure 2.14C), including Zbtb32
89

, Bach2

63

, Il9r

89

, Klf2

89

, and Ccr6
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13, 88,

. This cluster expressed low levels of S1pr2 (Figure

2.14D), which is important for GC retention

90

, but high levels of S1pr1 and Gpr183 (Figure
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2.14D), which are associated with GC egress

90, 91

. This transcriptional profile of MBC

precursors argues against their potential to continue to participate in GCs and affinity mature.
The MBC genes Zbtb32, Il9r, Klf2, and Ccr6 also were expressed by some cells
throughout clusters 0, 1, 2, and 4 and were co-expressed with Aicda and Jchain (Figure 2.14BC). Unlike cluster 3, clusters 0, 1, 2, and 4 express high levels of S1pr2 and low levels of Gpr183
and S1pr1, indicating GC retention, implying that these cells can still participate in GC reactions
(Figure 2.14D). These data suggest that cells with intermediate levels of MBC specification and
commitment might precede MBC precursor generation from the GC.
To functionally test whether committed MBC precursors continue to participate in GCs
or are formed de novo from GCs, we designed a lineage tracing model. We noted that MBC
precursors, but not other GC B cells, lack expression of Jchain (Figure 2.14B), a BLIMP1dependent marker of plasma cell potential

92, 93

. We thus generated mice carrying an IRES-

CreERT2 cassette in the 3’ UTR of Jchain and crossed them to animals with a ROSA26-loxPstop-loxP TdTomato cassette (TdT-Jchain mice). Tamoxifen treatment of these mice revealed
efficient labeling of GC B cells and LLPCs, with negligible labeling of other B cells or non-B
lineages (Figure 2.13E). We reasoned that at early timepoints post-vaccination, tamoxifen
treatment would preferentially mark GC B cells but leave MBC precursors mostly unlabeled. If
MBCs at later timepoints remained similarly unlabeled, these data would imply that low affinity
MBC precursors are committed early in the response yet continue to participate in GC reactions
(Figure 2.13F). In contrast, if the percentage of labeled mature and precursor MBCs at later
timepoints were substantially higher than early in the response, this would imply that MBC
commitment is not complete early in the response (Figure 2.13F). To test these models, TdTJchain mice were vaccinated against WNV, pulsed with tamoxifen at days 5 and 6 after
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vaccination, and TdTomato expression analyzed in DIII+ GCs, MBC precursors, and swIg
MBCs at different time points (Figure 2.14E). Antigen-specific GCs were efficiently labeled,
remaining above 60% TdTomato+ at both weeks 1 and 4 post-vaccination. In contrast, DIII+
MBC precursors were fully unlabeled at Day 7, but increased over time to approach that of GCs
by Day 28 (Figure 2.14F). Because the total number of antigen-specific MBC precursor cells
was very low at Day 7, we also examined the labeling frequency of polyclonal MBC precursors.
This was also quite low at Day 7 (6.5%), confirming the lack of Jchain expression in these
population of cells. At 28 days post vaccination, the frequency of labeled mature MBCs was
similar to the frequency of labeled MBC precursors (Figure 2.14F). These data argue against
prolonged participation in GCs by unlabeled and committed MBC precursors. Instead, these
results suggest that MBCs are specified and selected for relatively low affinity from GCs de novo
for at least the first few weeks of the response, which allows for their marked increase in affinity
over time.
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2.4 Discussion
Unlike LLPCs, MBCs can respond to antigen re-exposure by rapid proliferation and
differentiation to either plasma cells or secondary GC B cells, the latter of which can produce
new affinity-matured plasma cells and MBCs. These recall responses may be of particular
importance when mutants or genetically divergent strains of pathogens arise that escape serum
antibodies. Examples of such pathogens include HIV, which mutates continuously during
chronic infections; influenza viruses, which undergo antigenic drifts and shifts; and flaviviruses,
in which related but genetically distinct strains and serotypes co-circulate in overlapping
geographic regions. For each of these pathogens, efforts are underway to design vaccine
immunogens that would focus the antibody response to neutralizing epitopes. As an example,
sequential immunizations are envisioned in which MBCs are gradually guided to the target
antibody specificities that bind to antigens such as the CD4-binding site epitopes on HIV 94, 95, 96.
This strategy assumes the ability of immunogens to engage MBCs to re-initiate GC reactions.
Yet in mouse models of heterologous flavivirus challenges, we observed that the MBC
compartment was largely static after the primary vaccination or infection, with little ability to
generate new specificities through secondary GCs. Similar conclusions were reached in recent
influenza studies in both humans and mice

19, 97

. Thus, the underlying MBC biology may limit

the success of sequential immunization strategies. Clearly more details are needed on the cues
that allow for the generation and engagement of MBC subsets that can form secondary GCs.
MBCs are diversified relative to LLPCs to ensure greater antigenic coverage than can be
achieved by serum antibodies alone. Recent studies on responses to model antigens have
provided some potential mechanistic explanations for this property. MBC commitment in GCs
correlates with low affinity, lack of T cell help, and Bach2 expression 63. Reciprocally, only the
48

highest avidity cells in the GC receive sufficient T cell help to exit as LLPCs

60, 62

. In an

alternative model, signals in the GC may preferentially promote MBC commitment early and
switch to LLPC selection later in the response, thereby explaining differences in final avidity
98

7,

. Our findings on flavivirus-specific responses agree with and extend upon aspects of both

these models. First, we observed an early wave of formation that contributes to most of the
durable MBC population 7. Second, we observed a lower average final avidity of MBCs relative
to their LLPC counterparts

6, 7, 58, 63

. This result, along with observed differences in MBC

specificities relative to GCs throughout the response, argue in favor of active selection 63. Yet the
extent of MBC affinity maturation we observed was substantial and similar to that of LLPCs.
Instead, the germline precursor avidities were lower in MBCs relative to LLPCs, perhaps
explaining the differences in final avidities. Unlike responses to haptens or those observed with
BCR transgenics where single mutations impart large increases in avidity, polyclonal responses
against protein antigens affinity mature more gradually

99, 100

. Thus, a low starting binding

capacity may predispose to low final avidities and bias toward the MBC fate either through an
active selection mechanism, by limiting persistence in GCs before signals switch to promote
LLPCs, and/or by preferentially selecting MBC clones that improve affinities very rapidly prior
to this switch.
Low relative affinities could increase the breadth of MBC specificities and contribute to
recall responses in several ways. First, the low relative binding capacity of MBCs might allow
for affinity maturation in reverse, in which mutations in a pathogen in fact enhance recognition
by a subset of MBCs. Our previous work in fact revealed some evidence of such anticipatory
memory

10

. Second, a low avidity threshold might allow for a greater clonal diversity of MBC

specificities to be recruited into the primary response
49

101

. An implication of this mechanism is

that immunogen interactions with germline precursors can be manipulated to increase or
decrease final MBC and antibody diversity. This agrees with studies that have found other B cell
properties, such as proliferation, survival, and GC entry to be linked to germline affinity 57, 61, 101,
102, 103, 104, 105, 106

.

For flavivirus vaccines, the best strategy might be to restrict antibody and MBC diversity
to minimize weakly cross-neutralizing antibodies and ADE, as we found no evidence that such
antibodies could be redeemed through secondary GC reactions. DENV and ZIKV DIII-LR crossreactive monoclonal antibodies with ‘public’ clonotypes have been isolated from humans

42, 44

,

and JEV-WNV cross-reactive DIII-LR antibodies were observed both in our study and in
previous work 37. Our data suggest that such cross-neutralizing antibodies are likely rare, reactive
across only highly related strains, and may already exist prior to heterologous infections. As
corroborating evidence, heterologous DENV and ZIKV infections do not measurably alter the
pre-existing MBC pool in humans 107.
Structure-based immunogen design to minimize cross-reactive responses, even to
otherwise neutralizing epitopes, may achieve flavivirus type-specific immunity while minimizing
ADE. Several such efforts are underway already

108, 109, 110, 111

, yet our study offers some

additional insight. First, a ‘hidden’ repertoire of low affinity MBCs exists that is not necessarily
reflected in serum antibodies. These MBCs potentially can cross-react with conserved nonneutralizing epitopes across flaviviruses, such as DIII-non-LR and thus yield ADE-promoting
antibodies. Given that much of the target population for flavivirus vaccines is seropositive for at
least one flavivirus already, special attention might be needed to avoid pre-existing MBCs via
immunogen design. Second, for naïve individuals, immunogen multimerization and engineering
to enhance avidity, possibly to public germline DIII-LR antibodies
50

44

, may be an effective

strategy to limit the initial MBC diversity and focus the primary response on potently
neutralizing epitopes
vaccines

103, 113, 114

112

. Similar strategies have shown initial promise in models of HIV

, and our studies support these approaches for type-specific flavivirus

immunizations.
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2.5 Materials and Methods
Mice. All animal procedures used were approved by the Animal Care and Use Committees at
Washington University and the University of Arizona. WNV and JEV infections were
performed according to A-BSL3 standards. All mice were housed and bred in pathogen-free
facilities. C57BL6/N mice were obtained from the National Cancer Institute. Aicdaf/f mice
were generated by injecting targeted C57BL/6N embryonic stem line (HEPD0615_4_B08,
Aicdatm1a(EUCOMM)Hmgu, European Conditional Mouse Mutagenesis Program) into B6 albino
(Jackson Laboratory) mice by the Transgenic Knockout Microinjection Core facility at
Washington University in St. Louis. Pups were first crossed to ROSA26::FLP2 (Jackson
Laboratory, Stock No: 008463) mice to remove the LacZ and neomycin resistance
sequences, and then to hCD20-TamCre mice

50

to generate Aicdaf/+ mice. Mice were then

maintained as either Aicdaf/f or Aicdaf/f/x hCD20-TamCre and littermates were used as controls.
The following primers were used for genotyping the Aicda allele: common forward 5’AGCCCCTCAGCCCTTTAATC-3’, wild-type reverse 5’- AGCTGGTGTTGTGTGCGAAG3’, Aicda targeted 5’- TCGTGGTATCGTTATGCGCC-3’. JchainCreERT2 mice were
generated by microinjecting Cas9-gRNA ribonucleoparticles into C57BL6/J zygotes alongside
an IRES-CreERT2 donor cassette targeting the 3’ UTR of Jchain. Targeted mice were crossed
to C57BL6/N mice and then to LoxP-Stop-LoxP (LSL)-TdTomato mice (Jackson Laboratory,
Stock No: 007914). Mice heterozygous for Jchain and LSL-TdTomato were used. Tamoxifen
treatment consisted of placing mice on tamoxifen for two weeks. For timed deletions, mice
were also gavaged for two consecutive days with 50 ug of tamoxifen dissolved in corn oil per
gram of mouse weight.
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DIII refolding and biotinylation
To generated biotinylated DIII, DIII sequences were cloned downstream of a modified pET21
expression vector containing 6x Histidine tag, AviTag (GLNDIFEAQKIEWH), and Thrombin
cut site

36

. WNV, ZIKV and JEV DIII proteins were refolded by oxidative refolding as

previously described

30, 37, 38

. Briefly, BL21(DE3) E. coli cells were used for autoinduction of

DIII cloned into the pET21 expression vector. The DIII protein was refolded from inclusion
bodies by oxidative refolding and purified by size exclusion. AviTagged DIII protein were
biotinylated

using

the

NIH

Tetramer

Core

Facility

biotinylation

protocol

(https://tetramer.yerkes.emory.edu/support/protocols#9).

Flow cytometry.
Single cell suspensions were prepared from bone marrow or spleen. Erythrocytes were lysed
using an ammonium chloride-potassium solution, and lymphocytes were isolated with
Hisopaque-1119 (Sigma-Aldrich) and density gradient centrifugation. Cells were resuspended in
PBS with 5% adult bovine serum and 2 mM EDTA prior to staining with antibodies and labeled
DIII-tetramers. The following antibodies were purchased from Biolegend: 6D5 (CD19)-Alexa
Fluor 700; GL7-FITC -PerCP-Cy5.5, - PE, or Pacific Blue; 90 (CD38)-BV510 or -APC-Cy7;
281-2 (CD138)-PE or -APC; RMM-1 (IgM)-APC; 11-26c.2a (IgD)-PerCP-Cy5.5, -PEDazzle594, -BV510, or -BV605; 16-10A1 (CD80)-PE, -Alexa Fluor 488, or -Brilliant Violet
421; TY25 (PD-L2)-Brilliant Violet 421 or -PE-Dazzle594; TY/11.8 (CD73)-APC-Cy7; B3B4
(CD23)-BV510; and RA3-6B2 (B220)-FITC. The following antibodies were purchased from
eBioscience: 11/41 (IgM)-PerCP-e710 and 4E3 (CD21/35)-FITC. Ephrin-B1-biotin was
purchased from R&D. The following antibodies were purchased from Bio X Cell: M1/70
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(CD11b), 2C11 (CD3), GK1.5 (CD4), 53-6.7 (CD8), and TER119. Labelled DIII tetramers were
generated by incubating biotinylated DIII with labelled streptavidin (Brilliant Violet 421,
Brilliant Violet 605, PE, or APC, all from Biolegend) at a 1:4 molar ratio, where 1/10th of the
total streptavidin was added to DIII every 10 minutes. DIII tetramers were diluted in PBS to 130
ug of DIII/mL, and cells were stained at 2.6 ug/mL of DIII tetramer per 107 cells for 20 min on
ice. Antigen-specific MBCs and GC B cells were enriched by depleting non-B cells, IgM+ and
IgD+ splenocytes cells by cellular panning. Splenocytes were stained with rat anti-CD4, CD8,
CD11b, CD3, Ter119, IgM, and IgD on ice for 20 min, wash, and then incubated on plates precoated with 1 ug/mL of mouse anti-rat IgG (3053-01, Southern Biotech) for 20 min at 4°C. The
non-adherent cell fraction was collected, washed, and then stained with MBC and GC B cell
surface markers (CD19, GL7, CD38, CD80, CCR6 and DIII tetramers). Antigen-specific bone
marrow plasma cells were subjected to CD138 enrichment prior to DIII-tetramer staining. Total
bone marrow cells were stained with 2 uL of anti-CD138 APC, cells washed and then stained
with anti-PE magnetic beads (0.5 uL/107 cells, Miltenyi Biotec). Positive enrichment of CD138expressing cells was performed using MACS LS columns (Miltenyi Biotec), where enriched
cells were stained with 2.6 ug/mL of DIII tetramers.

ELISA.
ELISA plates (9018, Corning) were coated overnight at 4°C in 0.1 M sodium bicarbonate buffer,
pH 9.5 containing 5 ug/mL of the appropriate domain III antibody, WNV E protein, or 4G2
mAb. All other incubation steps were performed at room temperature for 1 hour. Wash steps
were performed between each step using PBS + 0.05% Tween-20. Plates were blocked with
PBS + 2% BSA followed by serial dilutions of serum. Plates coated with 4G2 were further
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incubated with media containing WNV SVPs. Serum was probed with 0.1 ug/mL of biotinylated
anti-mouse IgG (715-065-151, Jackson ImmunoResearch Laboratories) or 0.14 ug/mL of
biotinylated anti-mouse IgM (115-065-075, Jackson ImmunoResearch Laboratories) and then
detected with streptavidin conjugated horseradish peroxidase (554066, BD biosciences). MAbs
were probed with 0.8 ug/mL of peroxidase conjugated anti-human IgG (709-035-149, Jackson
ImmunoResearch). Plates were developed using TMB (J61325, Alfa Aesar) and neutralized with
2N H2SO4. Optical density (OD) values were measured at 450 nm. Serum endpoint titer was
defined as the inverse dilution factor that is three standard deviations above background using
variable slope measurements and Prism software (GraphPad Software). OD values from mAbs
were normalized to the OD values of humanized E16 (NR-31082, BEI Resources) at each
dilution.

Neutralization Assays.
Serum was heat-inactivated at 56°C for 30 min. Serial dilutions of serum or mAbs were
incubated with 100 FFU of WNV-NY99 or JEV SA14-14-2 for 1 h at room temperature.
Serum/mAbs-virus complexes were added to a monolayer of Vero cells in a 96-well plate and
incubated at 37°C with 5% CO2 for 1 h. Cells were overlaid with 1% (w/v)
carboxymethycellulose in MEM supplemented with 2% FBS, 1x Pen-Strep, and 1x GlutaMax.
Plates were harvest 24 (WNV) or 36 (JEV) h later and fixed with 1% PFA in PBS. Plates were
incubated with 500 ng/mL of hE16 (for WNV) or JEV-31 (Fernandez, E. et al., mBio, 2018)
diluted in PBS + 0.1% saponin+0.1% BSA. hE16 was detected using 0.8 ug/mL of peroxidase
conjugated anti-human IgG, whereas JEV-31 was detected using 100 ng/mL biotinylated anti-
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mouse IgG followed by streptavidin-HRP. Foci were visualized using TrueBlue peroxidase
substrate (50-78-02, KPL) and enumerated on the CTL ImmunoSpot S6 Analyzer.

ELISpot Assays.
ELISpot plates (MSHAN4510, Millipore Sigma) were coated with 10 ug/mL of anti-mouse Ig
kappa (559749, BD biosciences) in PBS overnight at 4°C. Plates were blocked with complete
DMEM for 1 h. Bone marrow plasma cells were enriched on CD138 as described above and
plated in triplicates. Cells were incubated at 37°C with 5% CO2 for 16 h. Plates were washed
with PBS followed by PBS+0.05% Tween-20, incubated with 5 ug/mL of biotinylated WNV WT
or KT DIII diluted in PBS, 2% adult bovine serum and 0.05% Tween-20 and incubated at room
temperatures for 1 h. Plates were rinsed with PBS + 0.05% Tween-20 and then incubated with
streptavidin HRP diluted in PBS, 2% adult bovine serum, and 0.05% Tween-20 at room
temperatures for 1 h. Wells were washed one last time with PBS + 0.05% Tween-20 and PBS.
Spots were developed using TrueBlue peroxidase substrate and enumerated on the CTL
ImmunoSpot S6 Analyzer. The total number of DIII-specific bone marrow plasma cells was
calculated by multiplying the number of enumerated spots by the plating dilution factor. The
value was then divided by the total number of bone marrow cells.

WNV SVP production.
Lenti-X 293T cells were transfected with WNV prM-E construct 115 using GeneJuice transfection
reagent. Supernatants were collected 48 h later, filtered using a 0.2 um filter, aliquoted, flash
frozen, and stored at -80°C.
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Immunizations.
Mice were administered two doses of inactivated WNV Innovator vaccine (Valley Vet Supply)
by intraperitoneal injection on days 1 and 2 10. Biotinylated ZIKV WT

38

and A310/T335 (LR

mutant) DIII were tetramerized with streptavidin at a 1:4 molar ratio, where 50 ug of tetramer
was mixed with 100 uL of AddaVax vaccine (Invivogen) and then administered to mice by
intraperitoneal injection.

MAb generation and purification.
Antigen-specific MBCs were sorted using a FACSAria II and cultured as previously described 10.
Briefly, each well of a 96-well plate were seeded with 30,000 mitomycin C-treated BAFF +
CD40L + NIH 3T3 cells 10, one day prior to seeding individual MBCs. Sorted MBCs were cocultured with the feeder cells in the conditioned 3T3 complete DMEM medium (DMEM, 10%
FBS, 1x penicillin-streptomycin, 1 mM sodium pyruvate, 1x nonessential amino acids, and 2
mM GlutaMax) containing 1 µg/ml pokeweed mitogen lectin (Sigma-Aldrich), 10 µg/ml
lipopolysaccharide (from E. coli 0.111:B4; Sigma-Aldrich), 1 µg/ml phosphorothioated murine
CpG (5′-TCCATGACGTTCCTGATGCT-3′; Integrated DNA Technologies), 16 ng/ml mIL-2,
10 ng/ml mIL-6, 17 ng/ml mIL-10 (PeproTech), 10 mM HEPES, and 50 µM β-mercaptoethanol).
Supernatant was collected after 6 days of culture, and DIII specificity assessed by ELISA. V(D)J
sequences were amplified as described in (Tiller, 2009) and cloned into modified heavy
(Addgene plasmid # 8079) and light chain (Addgene plasmid # 80796) expression vectors

116

.

The modified heavy chain expression contains a G4S linker sequence and an AviTag sequence at
the 3’ end of the hIgG1 sequence. Single antigen-specific LLPCs from the bone marrow were
sorted into catch buffer containing 0.1M Tris pH 8.0 and RNase inhibitor
57

117

and flash frozen.

V(D)J sequences were isolated according to a previously published protocol

118

. Briefly, cDNA

was generated, two rounds of nested PCRs performed to amplify the V(D)J sequences, and then
V(D)J sequences cloned into the modified heavy and light chain expression vectors.

Lenti-X 293T cells (Clontech) used for transfections were maintained in complete DMEM
containing 10% ultra-low IgG FBS (ThermoFisher), 1x penicillin-streptomycin, 1 mM sodium
pyruvate, 1x nonessential amino acids, and 2 mM GlutaMax. Transfections were performed
using GeneJuice (EMD Millipore Novagen). Somatically hypermutated mAbs were produced by
co-transfecting heavy chain construct, light chain construct, and a BirA ligase construct.
Germline reverted mAbs were produced by co-transfecting heavy and light chain constructs.
Fresh media was supplemented every other day. Six days after transfection, supernatants were
collected, cellular debris filtered, and then mixed with Protein G IgG Binding Buffer (Thermo
Scientific) at a 1:1 ratio. MAbs were purified from the supernatant by Protein G (GE Life
sciences) affinity chromatography. Purified antibodies were concentrated and buffer exchanged
with PBS containing 0.1% sodium azide using an Amicon® Ultra-15 Centrifugal Filter Unit (30
kDa membrane).

BLI Binding Assays.
The binding affinity of affinity matured mAbs to WNV WT DIII was assessed by BLI using an
Octet Red384. The buffer used contained 150 mM NaCl, 10 mM HEPES, 3 mM EDTA, 0.005%
Tween20, and 1% BSA, pH 7.4. Biotinylated mAb was loaded onto streptavidin biosensors
(ForteBio) at 5 ug/mL for 3 minutes. The association and dissociation of antibody to WNV WT
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DIII was measured at 30°C. Data were analyzed using the ForteBio DataAnalysis 11.0 software,
and fitted to a 1:1 binding model.

Single cell RNA-seq.
WNV DIII-specific GC B cells (CD19+GL7+EphrinB1+IgD-) were sorted using a FACS AriaII
and prepared and processed according to 10x Genomics instructions for Single Cell Protocols
Cell Preparation Guide and Chromium Single Cell V(D)J Reagents kit. Sequencing files were
processed using the CellRanger program (10x Genomics), where minimum read cutoffs were
kept at default settings. Sequences were further processed and visualized using Seurat

119, 120

.

Cells containing more than 5% mitochondrial genes were discarded. UMAP clusters of cells
were determined based on global gene expression or on cell cycle genes.

GC mutation analysis.
WNV DIII-specific GC B cells (CD19+GL7+IgD-CD38-) from WT mice. were sorted 7, 14, 21,
and 28 days after WNV vaccination. RNA was using the NucleoSpin RNA XS kit (MachereyNagel) per manufacturer’s instructions. cDNA synthesis was performed as previously described
118

. IgG immunoglobulin transcripts were amplified with the following primers: msVHEstdseq1

5’ACACTCTTTCCCTACACGACGCTCTTCCGATCTGGGAATTCGAGGTGCAGCTGCAGG
AGTCTGG-3’

and

commonCgstdseq2

5’-

GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCARKGGATRRRCHGATGGGG-3’.
A final amplification with P5 forward Stdseq1 and P7 reverse Stdseq index primers were used as
previously published

121

. Samples were pooled, purified, and then sequence dusing Illumina
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Miseq v3 2x250 platform using previously published 121. Forward and reverse reads were paired
using the default settings of PEAR

122

. Paired reads were further analyzed using Migmap

(https://github.com/mikessh/migmap) where full length VDJ sequences were merged and
corrected for PCR errors. Somatic hypermutation information was extracted using the Migmap
post-analysis command.

Immunoblotting.
Aicdaf/f TamCre and Aicdaf/f mice were immunized with 8x108 sheep red blood cells (Lampire)
by intraperitoneal injection. GC B cells were sorted on a FACS Aria II at different timepoints
after immunization. Cells were lysed in Laemmli buffer containing 2% SDS and 5% 2mercaptoethanol and stored at -20°C until analysis. Cell lysates were separated by 10% SDSPAGE and transferred to PVDF membrane (Roche). The membranes were probed with 20 ug/mL
of anti-AID monoclonal antibody (mAID-2, eBioscience). The signal was detected using a
Luminata HRP substrate (Millipore). Signal from the horseradish peroxidase was quenched by
incubating the membrane with 30% H2O2 for 10 min. The membrane then was probed with antiERK2 (Santa Cruz, C-14) antibody as a loading control. The signal was detected using a
Luminata HRP substrate.

Statistics.
All statistical tests were conducted using Graphpad Prism and are detailed in each figure legend.
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Figure 2.1 Validation of Aicda f/f mice.
(A) Targeting construct for Aicda. (B) PCR genotyping of the Aicda allele to confirm targeting
and absence of neomycin resistance cassette. (C) Aicdaf/f x TamCre mice were immunized
with sheep red blood cells and treated with tamoxifen starting on day 7 after immunization.
CD19+GL7+ cells were sorted at different days after tamoxifen and immunoblotted for AID.
ERK2 level (probed with anti-ERK2 antibody) was used as the loading control. (D) Aicdaf/f x
TamCre mice were treated with tamoxifen for two weeks and then immunized with the
inactivated WNV vaccine. Serum was collected 12 days later to confirm absence of antiWNV WT DIII IgG antibodies. Mean values ± SEM are shown.
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Figure 2.2 MBCs do not require additional affinity maturation to respond to
heterologous flavivirus challenges.
(A) WNV-vaccinated and naïve mice were bled before (D0) and 14 days after JEV
vaccination. Serum IgG endpoint titers against JEV WT DIII were calculated as the reciprocal
serum dilution that was three standard deviations above background. Endpoint titers were
calculated as the reciprocal serum dilution that was three standard deviations above
background. Each symbol represents an individual mouse. **p < 0.01; paired student’s t-test.
Data comes from one experiment. (B) Schematic representation of the experimental setup for
WNV vaccination and JEV recall responses. (C) Serum from WNV-immune Aicda f/f x
TamCre (AID cKO) and Aicda f/f (AID WT) was collected 70 days after JEV vaccination.
Levels of WNV DIII- and JEV DIII-specific IgG were measured by ELISA. Mean endpoint
titers ± standard error of the mean (SEM) are shown. Each symbol represents an individual
mouse. (D) IgG levels, shown as OD450nm values for 1:50 diluted serum, collected in (C), for
binding to JEV WT and JEV ESAK DIII. Each symbol connected by lines represents paired
values from an individual mouse. Data are pooled from two independent experiments. (E)
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Neutralizing antibody titers (1/IC50) to JEV were measured by a focus reduction
neutralization test (FRNT) from serum collected in (C). Mean ± SEM are shown; each symbol
represents an individual mouse. (F) Schematic representation of the experimental setup for
ZIKV DIII immunization and subsequent JEV recall responses. (G) Serum from ZIKV DIIIimmunized AID cKO and AID WT was collected 28 days after JEV vaccination. Levels of
ZIKV DIII and JEV DIII specific IgG antibodies were measured by ELISA. Mean endpoint
titers ± SEM are shown. Each symbol represents an individual mouse. Data are pooled from
two independent experiments.
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Figure 2.3 IgM responses after heterologous JEV vaccination.
(A) Validation of JEV ESAK DIII by ELISA. JEV DIII-LR specific mAb JEV-31 37 was used
to confirm loss of the LR epitope. Wild-type mice were immunized with JEV ESAK DIII, and
immune serum was used to probe for binding to JEV WT and ESAK DIII. Data from 1
experiment is shown. Mean values ± SEM are shown. (B) Serum from WNV-immune Aicda
f/f x TamCre (AID cKO) and Aicda f/f (AID WT) was collected before, 14 and 28 days after
JEV vaccination. Levels of JEV WT DIII and JEV ESAK DIII specific IgG antibodies were
measured by ELISA. Endpoint titers were calculated as the reciprocal serum dilution that was
three standard deviations above background. Mean endpoint titers ± SEM are shown. Each
symbol represents an individual mouse where matched samples are connected by a line. Data
is from one experiment. (C) Serum from WNV-immune AID WT and AID cKO mice was
collected ten weeks after JEV vaccination. JEV WT and JEV ESAK DIII specific IgM levels
are shown as the OD450nm values from serum diluted 1:50. Each symbol represents an
individual mouse. Mean ± SEM are shown. Data are pooled from two independent
experiments. (D) Serum from ZIKV DIII immunized AID WT and AID cKO was collected
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before and 28 days after JEV vaccination. Levels of JEV WT DIII and JEV ESAK DIII
specific IgG antibodies were measured by ELISA. Endpoint titers were calculated as the
reciprocal serum dilution that was three standard deviations above background. Mean
endpoint titers ± SEM are shown. Each symbol represents an individual mouse where matched
samples are connected by a line. Data are pooled from two independent experiments. (E)
Serum from ZIKV-immune AID WT and AID cKO mice was collected four weeks after JEV
vaccination. JEV WT and JEV ESAK DIII specific IgM levels are shown as the OD450nm
values from serum diluted 1:50. Data are pooled from two independent experiments. (F)
Schematic representation of DENV and ZIKV recall responses. (G) The frequency of ZIKV
DIII-specific MBCs and LLPCs were quantified by flow cytometry and ELISPOT,
respectively. Mice challenged with only ZIKV were used to delineate the naïve B cell
responses. AID WT (2° only) is calculated by subtracting the average WT primary response
value from the AID WT (1° and 2°) values. Mean values ± SEM are shown; each symbol
represents one mouse. Data are pooled from two independent experiments.
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Figure 2.4 Gating strategy for memory B cell subsets.
Gating strategy for MBC subsets based on CD80 and CCR6 expression. Cells are gated on
CD19+GL7- and IgM+IgD+, IgM+IgD-, or swIg (IgM-IgD-) expression. Representative data
from 2 experiments are shown.
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Figure 2.5 Plasma cell-biased MBCs recognize and respond to heterologous antigens.
(A) Mice were vaccinated with inactivated WNV vaccine and the number of DIII-specific
cells in different MBC subsets was calculated by flow cytometry 8-12 weeks later. WNVvaccinated mice are compared to naïve animals. Mean ± SEM are shown; each symbol
represents an individual mouse. Data are pooled from two independent experiments. *p <
0.05; student’s two-tailed t test for each subset. (B) Representative flow cytometry plots
showing the cross-reactivity of WNV DIII-LR and WNV DIII non-LR cells to JEV DIII-LR
and JEV DIII non-LR cells. WNV DIII-binding cells were enriched from 5 pooled spleens
from WNV-vaccinated mice and then probed for JEV WT and ESAK DIII reactivity. (C) Sera
from WNV-immune mice, collected in Figure 1A, were assessed for WNV WT and WNV KT
DIII binding before (D0) and 14 days post JEV vaccination. Endpoint titers were calculated as
the reciprocal serum dilution that was three standard deviations above background. Each
symbol represents an individual mouse. **p < 0.01; matched two-way ANOVA. Data comes
from one experiment. (D) The frequency of WNV DIII-specific GC B cells (CD19+GL7+IgDCD38-) 7 and 14 days after JEV vaccination of WNV-immune mice was quantified by flow
cytometry. A representative plot of DIII-specific GC B cells is shown on the left and
quantified on the right. Mean ± SEM are shown; each symbol represents an individual mouse.
Data comes from one experiment.
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Figure 2.6 MBCs are actively selected from GC B cells.
(A) Mice were immunized with WNV inactivated vaccine and DIII-specificities in GC and
MBC compartments were enumerated by flow cytometry at days 7, 14, 21, 28 and 56+. A
representative plot of DIII-specific GC B cells is shown on the left and quantified on the right.
Mean frequencies ± SEM are shown; each symbol represents an individual mouse. *** p <
0.001, **** p < 0.0001; paired student’s t-test. Data are pooled from two independent
experiments. (B) The frequencies of WNV DIII-LR and WNV DIII non-LR binders in swIg
CD80+CCR6+ MBCs were quantified by flow cytometry. A representative plot of DIIIspecific MBCs is shown on the left and quantified on the right. Mean values ± SEM are
shown; each symbol represents an individual mouse. *** p < 0.001, **** p < 0.0001; paired
student’s t-test. Data are pooled from two independent experiments. (C) Ratios of WNV DIII
non-LR to WNV DIII LR-specific cells were quantified for GC B cells and MBCs using
values in (A) and (B). Mean values ± SEM are shown. *p < 0.05, ** p < 0.01, *** p < 0.001,
**** p < 0.0001; paired student’s t-test. (D) The frequency of CD38+CCR6+ expressing MBC
precursor cells within WNV DIII-LR and WNV DIII non-LR specific GC B cells
(CD19+GL7+IgD-) was quantified by flow cytometry. The gating strategy is shown on the top
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with a representative CD38+CCR6+ gate shown for DIII-LR cells. Mean values ± SEM are
shown; each symbol represents an individual mouse. Data are pooled from two independent
experiments.
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Figure 2.7 Isolation of mAbs from MBCs and LLPCs.
(A) Gating strategy for WNV DIII-specific LLPCs. LLPCs were first assessed for surface B
cell receptor expression by analyzing surface kappa expression. LLPCs in the bone marrow
were enriched for CD138 expression followed by WNV WT DIII staining with two different
tetramers. (B) Wild-type mice were immunized with inactivated WNV vaccine, and DIIIspecific MBCs and LLPCs were sorted at least 8 weeks after vaccination. Gating strategy for
CD19+GL7- WNV DIII-specific MBCs. Splenocytes were depleted of CD3, CD4, CD8,
CD11b, Ter119, IgM and IgG prior to sorting. (C) Reverse orientation ELISA of a subset of
DIII-specific mAbs to measure monovalent affinities. ELISA plates were coated with a fixed
concentration of mAbs and incubated with increasing concentrations of WNV WT DIII. Mean
values ± SEM are shown. (D) Example binding curves for representative MBC and LLPC
mAbs (left, middle) generated by biolayer interferometry with increasing concentrations of
WNV WT DIII. Binding curves were fit to a 1:1 binding model using ForteBio’s analysis
software. The panel below each binding curves shows steady-state analysis results (KD,
equilibrium), plotted as the binding response (nm) versus concentration of DIII, also shows
binding saturation. A Scatchard plot, shown as an insert in the steady-state analysis panels,
suggests single binding affinity. The binding association and dissociation constants were
calculated and plotted on the right. Mean ± SEM are shown; each symbol represents one mAb.
80

Figure 2.8 MBCs have lower avidity for their antigens than do LLPCs.
(A) Monoclonal Abs from WNV-immune mice were isolated from MBCs and LLPCs, and
WNV DIII reactivity was confirmed by ELISA. MAb binding curves for WNV WT DIII were
performed using ELISA. Mean ± SEM are shown. *p < 0.05; 2-way ANOVA. (B) Binding
affinity (KD, kinetic) to WNV WT DIII for a subset of mAbs was determined by biolayer
interferometry. Mean ± SEM are shown; each symbol represents one mAbs. n.s. indicates p >
0.05; Mann-Whitney test. (C) MAb binding curves for WNV subviral particles (SVPs) were
performed by ELISA. Mean ± SEM are shown. ****p < 0.0001; 2-way ANOVA.
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Figure 2.9 Deletion of AID during GC reactions does not impair class switching or
differentiation of MBCs and LLPCs.
(A) Frequencies of isotype switched (IgM-IgD-) GC B cells (CD19+GL7+) 7 and 14 days after
immunization of wild-type mice with inactivated WNV vaccine as measured by flow
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cytometry. Mean values ± SEM are shown. Each symbol represents one mouse. Data are
pooled from two independent experiments. (B) WT mice were immunized with inactivated
WNV vaccine. WNV DIII+ GC B cells (CD19+GL7+IgD-) were sorted at different time points
and IgH repertoire analysis was performed by MiSeq. The total number of replacement
mutations for IgH is shown for each week. (C) WT mice were immunized with inactivated
WNV vaccine, and the number of DIII-specific bone marrow plasma cells were enumerated by
ELISPOT at different time points. Representative wells are shown on the left and quantified
on the right. Mean values ± SEM are shown. Each symbol represents one mouse. Data are
pooled from two independent experiments. (D) Schematic of experiments to test for Cre
toxicity. Sera were collected 28 days after vaccination and probed for anti-WNV WT DIII and
E protein IgG antibodies. Mean values ± SEM are shown. (E) WNV DIII-specific LLPC
numbers after WNV vaccination and AID deletion were enumerated by ELISPOT. Mean
values ± SEM are shown. Each symbol represents one mouse. Data are pooled from two
independent experiments. (F) Serum from mice after WNV vaccination and AID deletion was
collected 8 weeks post-immunization, and IgM antibodies were probed for WNV E reactivity
by ELISA. Mean values ± SEM are shown. Data are pooled from two independent
experiments.
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Figure 2.10 Absolute affinity thresholds do not segregate MBCs from LLPCs in vivo.
(A) Experimental setup to temporally ablate AID during ongoing GC reactions. (B)
Frequencies of WNV DIII-LR and WNV DIII non-LR specific MBCs were quantified by flow
cytometry for each AID genotype and deletion group. Mean values ± SEM are shown; each
symbol represents an individual mouse. Data are pooled from two independent experiments.
(C) Serum IgG endpoint titers for WNV WT and WNV KT DIII were calculated by ELISA.
Mean values ± SEM are shown. Each symbol represents an individual mouse. Data are pooled
from two independent experiments. **p < 0.01 and ***p < 0.001; matched 2-way ANOVA.
(D) Serum from week 1 AID deletion was assessed for WNV SVP binding by ELISA. Mean
values ± SEM are shown.
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Figure 2.11 WNV DIII-LR and WNV DIII non-LR naïve and precursor cells are not
selected from distinct B cell subsets.
(A) Spleens from naïve mice were enriched for WNV WT and KT DIII tetramers binding.
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Frequencies of antigen-specific cells in the follicular (FoB) and marginal zone (MZ) B cell
compartments were enumerated by flow cytometry. A representative flow cytometry plot is
shown on the left and quantified on the right. Mean values ± SEM are shown. (B) The
frequency is shown of V, D, and J immunoglobulin heavy chain gene usage (top) or light chain
V and J gene usage (bottom) from mAbs derived from MBCs and LLPCs. (C) Frequencies of
WNV DIII-LR and WNV DIII non-LR-specific cells in Hardy Fractions E (Fr. E) and F (Fr. F)
were enumerated by flow cytometry. A representative plot is on the left and quantification is
shown in the middle. The IgM geometric mean fluorescence intensities (gMFI) of WNV DIIILR and WNV DIII-non LR specific cells in Hardy Fractions E and F are quantified on the
right. Mean values ± SEM are shown. *p < 0.05; matched 2-way ANOVA. (D) The number
of silent and total mutations in the heavy and light chains of the isolated panels of mAbs are
plotted. Mean ± SEM are shown; each symbol represents one mAb. *p < 0.05; Mann-Whitney
test. (E) WT mice were immunized with inactivated WNV vaccine. WNV DIII+ MBCs
(CD19+GL7-IgD-IgM-CD80+CCR6+) and WNV DIII+ bone marrow PCs (CD138hiIgM-) were
sorted at different time points and IgH repertoire analysis was performed by MiSeq. The total
number of non-silent mutations for IgH is shown for each week. Mean ± SEM are shown.
****p < 0.0001; Kruskal-Wallis test.
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Figure 2.12 Germline affinities of MBC-derived antibodies are lower than those from
LLPCs.
(A) MAbs isolated in Figure 4 were reverted to their germline sequences, and binding curves
against monomeric WNV WT DIII and SVPs were measured by ELISA. Mean values ± SEM
are shown. ***p < 0.001 and ****p < 0.0001; 2-way ANOVA. (B) The total number of
replacement mutations in the heavy and light chains of the isolated panels of mAbs are plotted.
Mean ± SEM are shown; each symbol represents one mAb. (C, D) ELISA binding curves for
monomeric WNV WT DIII (C) and WNV SVPs (D) are compared for germline-reverted and
somatically-mutated mAbs from MBCs and LLPCs. Mean ± SEM are shown. Mean ± SEM
are shown. ****p < 0.0001; two-way ANOVA.
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Figure 2.13 Single cell RNA sequencing and lineage tracing validation.
(A) Gating strategy to sort mature GC B cells one week after WNV vaccination of wild type
mice. Splenocytes were pre-enriched for GL7 expression. (B) UMAP plot indicating cell cycle
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stage for each cluster. (C) UMAP plot showing expression level of Bcl6. (D) UMAP plots
showing expression of light zone (Cd86) and dark zone (Foxo1 and Cxcr4) genes. (E) Jchain
expression in GC B cells was confirmed by crossing Jchain to LSL-TdTomato mice and
administering tamoxifen for two weeks. TdTomato expression was quantified for B cells
(CD19+ in the spleen or B220+ in the bone marrow), plasma cells (PC, CD138+), non-B cells
(B220-CD138- in bone marrow, CD19-GL7-CD138- in spleen), and GC B cells (CD19+GL7+).
Mean values ± SEM are shown. (F) Expected results for TdT-Jchain mice if MBCs are
committed early and continue to participate in GCs or if there is continuous selection of
MBCs.
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Figure 2.14 MBCs are continuously selected from GCs.
(A) DIII-specific GC B cells (CD19+GL7+IgD-EphrinB1+) were isolated one week after WNV
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vaccination, subjected to single cell RNA-sequencing and analyzed using Seurat. UMAP plot
is shown of DIII-specific GC B cells with each uniquely colored cluster segregated by
differential transcriptional profiles. (B) UMAP plots highlighting the gene expression level per
cell for GC genes Aicda and Jchain. (C) UMAP plots highlighting the gene expression level
per cell for MBC genes. (D) UMAP plots highlighting the gene expression level for GC egress
(Gpr183 and S1pr1) and retention (S1pr2) genes. (E) Schematic representation of GC lineage
tracing experiment. (F) A representative histogram for TdTomato expression in polyclonal
MBC precursors (CD19+GL7+IgD-IgM-CD38+EfnB1+) is shown (left). The frequency of
TdTomato expression in the DIII+ and polyclonal MBC precursor, DIII+ GC B cells
(CD19+GL7+IgD-CD38-EfnB1+) and DIII+ swIg MBC populations is quantified by flow
cytometry (right). Mean ± SEM are shown. *p < 0.05; paired Student’s t test for each
population.
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MBC Clone
81D5
82C7
84F8
87C8
8A2
9A10
9B2
9C4
9E12
9F7
2F2
4C1
83G4
8C5
8D3
8G3

Reactivity
DIII-LR
DIII-LR
DIII-LR
DIII-LR
DIII-LR
DIII-LR
DIII-LR
DIII-LR
DIII-LR
DIII-LR
DIII non-LR
DIII non-LR
DIII non-LR
DIII non-LR
DIII non-LR
DIII non-LR

VH
IGHV1-76
IGHV1-55
IGHV1-85
IGHV1-55
IGHV1-72
IGHV1-55
IGHV1-55
IGHV1-39
IGHV1-55
IGHV1-85
IGHV1-39
IGHV1-71
IGHV6-3
IGHV5-4
IGHV1-64
IGHV1-22

DH
IGHD1-3
IGHD2-3
IGHD2-3
IGHD2-3
IGHD2-4
IGHD1-1
IGHD1-1
IGHD2-12
IGHD3-3
IGHD1-1
IGHD2-12
IGHD2-1
IGHD1-1
IGHD2-2
IGHD2-13
IGHD3-2

JH
IGHJ4
IGHJ4
IGHJ4
IGHJ2
IGHJ3
IGHJ2
IGHJ3
IGHJ4
IGHJ2
IGHJ1
IGHJ4
IGHJ3
IGHJ2
IGHJ3
IGHJ3
IGHJ3

VK
IGKV6-25
IGKV6-25
IGKV3-4
IGKV6-25
IGKV6-17
IGKV6-25
IGKV6-25
IGKV6-25
IGKV6-25
IGKV6-25
IGKV1-135
IGKV4-55
IGKV4-79
IGKV8-27
IGKV4-55
IGKV6-17

JK
IGKJ5
IGKJ2
IGKJ1
IGKJ1
IGKJ2
IGKJ5
IGKJ1
IGKJ1
IGKJ5
IGKJ5
IGKJ1
IGKJ5
IGKJ5
IGKJ2
IGKJ4
IGKJ1

LLPC Clone
221A2
221A6
725A4
725A9
725B11
725B1
725C5
725D3
725D9
725E2
725F10
725G11
725G6
725G7
725H11
725H5
626A3
626A7
725B4
626C1

Reactivity
DIII-LR
DIII-LR
DIII-LR
DIII-LR
DIII-LR
DIII-LR
DIII-LR
DIII-LR
DIII-LR
DIII-LR
DIII-LR
DIII-LR
DIII-LR
DIII-LR
DIII-LR
DIII-LR
DIII-LR
DIII-LR
DIII non-LR
DIII non-LR

VH
IGHV1-55
IGHV1-9
IGHV1-55
IGHV1-55
IGHV1-76
IGHV1-76
IGHV5-9
IGHV1-76
IGHV1-52
IGHV1-55
IGHV1-9
IGHV1-85
IGHV1-76
IGHV1-55
IGHV1-61
IGHV1-85
IGHV1-72
IGHV1-55
IGHV1-82
IGHV1-26

DH
IGHD2-1
IGHD2-1
IGHD2-1
IGHD2-1
IGHD4-1
IGHD6-3
IGHD1-1
IGHD1-1
IGHD2-3
IGHD1-1
IGHD2-2
IGHD1-1
IGHD4-1
IGHD1-1
IGHD2-2
IGHD1-1
IGHD1-3
IGHD1-1
IGHD2-1
IGHD2-4

JH
IGHJ4
IGHJ2
IGHJ2
IGHJ2
IGHJ2
IGHJ4
IGHJ2
IGHJ2
IGHJ3
IGHJ2
IGHJ2
IGHJ2
IGHJ2
IGHJ2
IGHJ4
IGHJ3
IGHJ3
IGHJ2
IGHJ2
IGHJ2

VK
IGKV6-25
IGKV6-25
IGKV6-25
IGKV6-25
IGKV6-25
IGKV6-25
IGKV6-25
IGKV6-25
IGKV4-55
IGKV6-25
IGKV6-25
IGKV6-25
IGKV6-17
IGKV6-25
IGKV3-10
IGKV6-25
IGKV6-25
IGKV6-25
IGKV9-124
IGKV3-2

JK
IGKJ5
IGKJ5
IGKJ5
IGKJ5
IGKJ4
IGKJ5
IGKJ1
IGKJ2
IGKJ5
IGKJ5
IGKJ2
IGKJ5
IGKJ5
IGKJ1
IGKJ1
IGKJ5
IGKJ4
IGKJ5
IGKJ4
IGKJ1

Table 2.1. V, D, and J gene usages for mAbs derived from MBCs and LLPCs.
MAbs isolated in Figure 2.8 were subject to V(D)J gene usage analysis for both the heavy (H)
and light (K) chains. IMGT nomenclature is used.
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Chapter 3:
Defining the role of ZBTB38 in B cell responses

This work was performed in collaboration with Deepta Bhattacharya. Personal contributions
include the design and carrying out of selected experiments, data analysis, and writing of this
work.
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3.1 Abstract
Long-term B cell mediated immunity is provided by long-lived plasma cells (LLPCs) and
memory B cells (MBCs). LLPCs secrete antibodies to provide sterilizing immunity whereas
MBCs provide protection only after reactivation and differentiation into plasma cells. LLPCs
and MBCs primarily differentiate from germinal center (GC) B cells. Thus, these three B cell
compartments are critical for generating durable immunity. Members of the broad complex,
tram track, bric-a-brac and zinc finger (BTB-ZF) family of transcription factors include BCL-6,
ZBTB20, and ZBTB32.

These transcription factors regulate key aspects of B cell responses.

BCL-6 is essential for GC formation. ZBTB20 regulates the durability of LLPC responses in an
adjuvant dependent manner. ZBTB32 is important for restricting the durability of memory B
cell recall responses. ZBTB38 is another member of the BTB-ZF family, whose functional
importance in hematopoiesis and B cells has not been characterized. Here, we demonstrate that
ZBTB38 is dispensable for the development of many mature hematopoietic lineages as well as
for both primary and secondary B cell responses to a hapten antigen.
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3.2 Introduction
Humoral immunity to an infection or vaccination is mediated by long-lived plasma cells
(LLPCs) and memory B cells (MBCs), which have distinct antigen specificities and therefore
mediate different aspects of immunity 1.

LLPCs constitutively secrete antibodies, and are

important for providing protection against re-infection by the same pathogen. Memory B cells,
on the other hand, can only provide protection after re-activation by a cognate antigen by rapidly
differentiating into plasma cells. Recent studies have identified the broad complex, tram track,
bric-a-brac and zinc finger (BTB-ZF) family of transcription factors as key regulators in B cell
development. BTB-ZF family members are involved in many cellular processes by binding
DNA through its variable number of C-terminal zinc finger domains and recruiting SMRT corepressors and histone deacetylases to its N-terminal BTB/POZ domain

2, 3, 4, 5, 6

. Notable

members include BCL-6, ZBTB20, and ZBTB32, where each member regulates distinct aspects
of B cell mediated immunity.

BCL-6 is important for germinal center (GC) formation 7,

ZBTB20 promotes durable immunity in an adjuvant dependent manner 8, 9, and ZBTB32 restricts
memory B cell recall responses

10, 11

. Thus, understanding the role of additional BTB-POZ

members in regulating B cell responses may provide further insight into how the durability of B
cell memory responses are established.
ZBTB38, also known as CIBZ (CtBP-interacting BTB zinc finger protein) is another
member of the BTB-ZF family, and can function either as a transcriptional repressor or activator
12

.

ZBTB38 transcriptional regulation occurs by binding primarily to sequence-specific,

methylated CpG sequences and recruiting transcriptional repressors or activators

13, 14, 15

.

ZBTB38 has been shown to repress overall transcription by inhibiting expression of MCM10, a
component of the pre-replication complex 16. Additionally, ZBTB38 can, directly or indirectly,
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regulate cell cycle progression, cellular differentiation, and apoptosis

17, 18, 19, 20, 21

. Given the

ability of ZBTB38 to regulate cell cycle progression and anti-apoptosis, we hypothesized that
ZBTB38 is important for regulating GC reactions, which require a balance between proliferation
and apoptosis.

Quantitative real-time PCR of different B cell subsets revealed elevated

expression of ZBTB38 in GC B cells and plasma cells compared to naïve B cells. Here, we
demonstrate that ZBTB38 deficiency does not impair primary or secondary B cell responses to a
hapten immunogen.
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3.3 Results
Generation and validation of ZBTB38 floxed mice.
To assess the role of ZBTB38 in vivo, we generated Zbtb38 floxed mice by targeting
exon 3 using CRISPR technology (Figure 3.1A).

NdeI and EcoRI restriction sites were

introduced near the 3’ LoxP and 5’ LoxP sites to screen for successful integration of the plasmid.
Correct targeting of exon 3 was confirmed by PCR and restriction enzyme digestions, where
genomic DNA sequences flanking exon 3 was amplified followed by single and double
restriction enzyme digests with NdeI and EcoRI (Figure 3.1B). Wild-type, targeted, and deleted
Zbtb38 mice can be differentiated using a set of three primers that flank the 5’ and 3’ LoxP
sequences (Figure 3.1C). To confirm deletion of Zbtb38 exon 3 at the genomic level, Zbtb38 f/f
mice were crossed to mice expressing CMV-Cre to obtain germline ZBTB38 deletion. Genomic
DNA from Zbtb38 f/f x CMV-Cre was amplified where deletion was confirmed by a 4 kb
reduction in PCR size (Figure 3.1D).

ZBTB38 germline deletion did not result in gross

developmental abnormalities. No differences in the number or size of ZBTB38 deficient and
wild-type mice were observed (data not shown).

ZBTB38 deficiency does alter the development of hematopoietic cells
ZBTB38 gene expression in multiple cell types was analyzed using available RNAsequencing data assembled by the ImmGen Consortium. A subset of cell types expressing
DESeq2 normalized ZBTB38 levels greater than 800 are shown in Figure 3.2A. Given the high
expression of ZBTB38 in hematopoietic stem cells (HSCs), and downstream lineages such as B
and T cells, we crossed Zbtb38 f/f mice to VavCre mice (Zbtb38 f/f x VavCre, ZBTB38 KO),
which result in ZBTB38 deletion in hematopoietic cells.
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We first assessed if ZBTB38 deficiency alters the development of hematopoietic lineages
under physiological conditions by quantifying the frequencies of different cell populations by
flow cytometry. We first focused on hematopoietic stem cells (HSCs, cKit+Sca1+Flk2-CD27+)
and progenitors with varying degrees of lineage commitment in the bone marrow

22

. HSCs

differentiate into multipotent progenitors (MPPs, cKit+Sca1+Flk2+CD27+) that can give rise to
both the myeloid and lymphoid lineages. MPPs can then differentiate into common myeloid
progenitors (CMPs, cKit+Sca1-Flk2+FcgR-) or common lymphoid progenitors (CLPs, cKit/lo

Sca1-CD27+FcgR-Flk2+IL7Ra+)23, 24. CLPs give rise to B, T, natural killer (NK), and innate

like cells (ILCs). CMPs give rise to basophils, eosinophils, mast cells, dendritic cells as well as
granulocyte monocyte progenitors (GMPs, cKit+Sca1-Flk2-FcgR+) 24. GMPs can then give rise to
neutrophils and monocytes.

We identified no statistically significant differences in the

frequencies of these progenitor populations between ZBTB38 WT and KO mice (Figure 3.2B).
Although ZBTB38 was not required for the maintenance and differentiation of hematopoietic
progenitors, it does not preclude the possibility that ZBTB38 is required for the development of
mature lineages.
To assess if mature hematopoietic lineages require ZBTB38 for their development, we
analyzed the frequencies of different peripheral blood mononuclear cell (PBMCs) populations.
We observed no differences between ZBTB38 WT and KO mice in the frequencies of B cells
(B220+), NK cells (NK1.1+), T (CD4+ or CD8+ B220-NK1.1-CD11b-), monocytes
(CD11b+Ly6ChiLy6G-), or neutrophils (CD11b+Ly6C+Ly6G+) (Figure 3.2C). Thus, ZBTB38 is
not required for the development or maintenance of these hematopoietic lineages. We next
reasoned that perhaps ZBTB38 functional importance occurs after cellular activation.
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ZBTB38 is highly expressed in germinal center B cells.
Further analysis of ImmGen’s RNA-sequencing data identified highest expression of
ZBTB38 in splenic, short-lived plasma cells (SLPCs, data not shown). However, ImmGen’s
microarray data identified highest expression of ZBTB38 in GC B cells (data not shown). Thus,
we decided to confirm ZBTB38 expression in GC B cells and SLPCs by quantitative real-time
PCR. Wild-type mice were immunized with alhydrogel-adjuvanted 4-hydroxy-3-nitrophenylacetyl (NP) conjugated to ovalbumin (OVA) and naïve B cells (CD19+CD138-), NP-specific
dark (CXCR4+) and light zone (CD86+) GC B cells (CD19+GL7+IgD-), and NP-specific SLPCs
(CD138+) were sorted 11 days after immunization. RNA was extracted from sorted cells and
quantitative real-time PCR performed to quantify ZBTB38 transcript levels.

GC B cells and

SLPCs contained 9- or 3-fold, respectively, higher expression of ZBTB38 compared to naïve B
cells (Figure 3.3). No differences in ZBTB38 expression were observed between light and dark
zone GC B cells. These data suggest that ZBTB38 might be functionally involved in primary
antibody responses.

ZBTB38 deficiency does not impair primary B cell responses.
To determine if ZBTB38 has a functional role in primary B cell responses, we first
examined GC reactions.

We immunized ZBTB38 WT and KO mice with NP-OVA and

quantified the frequency of NP-specific GC B cells 2 weeks later, which corresponds with peak
GC reactions

25

. We observed no differences in the frequencies of NP-specific GC B cells

between ZBTB38 WT and KO mice (Figure 3.4A), indicating that ZBTB38 is not required for
the expansion of NP-specific GC B cells. We next wondered if ZBTB38 is important for plasma
cell differentiation or antibody secretion. Although only SLPCs were assessed for ZBTB38
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expression, given the transcriptional similarity between SLPCs and LLPCs 26, it is possible that
ZBTB38 may also potentially regulate LLPC differentiation or function. Additionally, although
ZBTB38 deficiency does not alter antigen specific GC B cell expansion, it may impair plasma
cell differentiation or antibody secretion.
To assess both SLPC and LLPC function, ZBTB38 WT and KO mice were immunized
with alhydrogel-adjuvanted NP-OVA and NP-specific serum antibodies were quantified over
time by ELISA.

The levels of NP-specific antibodies, captured using NP16, were similar

between ZBTB38 WT and KO mice at all time points measured (Figure 3.4B). To specifically
quantify the level of high affinity antibodies in the serum by ELISA, low density antigen (NP4)
was used to probe for antibody binding. Low density NP (NP4) is used to capture antibodies
with slow off-rates, which is correlated with antigen high affinity. This contrasts with high
density NP (NP16), which can capture antibodies with slower off rates due to decreased distance
between NP molecules. Unlike the total number of NP-specific antibodies over time, which
plateaued two weeks after immunization, the number of high affinity antibodies increased
steadily over time and plateaued four weeks after immunization (Figure 3.4C). No difference in
the quantity of high affinity antibodies was observed between ZBTB38 WT and KO mice
(Figure 3.4C). Furthermore, the extent of affinity maturation, quantified as the ratio of NP4 to
NP16 endpoint titers, was similar between ZBTB38 WT and KO mice (Figure 3.4D). Possible
explanations for the similar serum antibody levels in ZBTB38 WT and KO mice include similar
frequencies for antigen-specific LLPCs or compensatory increased antibody secretion from
fewer LLPCs.
To differentiate between these two possibilities, the frequency of NP-specific LLPCs was
quantified by flow cytometry 8 weeks after alhydrogel-adjuvanted NP-OVA immunization of
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ZBTB38 WT and KO mice. The frequency of NP-specific LLPCs was similar between ZBTB38
WT and KO mice, suggestion that ZBTB38 does not have a functional role in plasma cells. Our
data thus far demonstrate that ZBTB38 is not required for either GC expansion or plasma cell
differentiation and function. We next speculated that perhaps the high expression of ZBTB38 in
GC B cells is important for initiating a transcriptional program required for subsequent memory
B cell differentiation or function.

ZBTB38 deficiency does not alter recall responses.
To determine if ZBTB38 expression is required for MBC differentiation, the frequency of
NP-specific memory B cells (CD19+GL7-IgM-IgD-CD80+CCR6+) was quantified in ZBTB38
WT and KO mice 8 weeks after immunization with alhydrogel-adjuvanted NP-OVA.

No

difference in the frequency of NP-specific MBCs was observed (Figure 3.5A). Thus, ZBTB38
is not required for the differentiation of memory B cells, but may still be required for MBC
reactivation. To determine if ZBTB38 deficiency alters recall responses, splenocytes from
ZBTB38 WT and KO mice were adoptively transferred into allotype-distinct naïve IgHa hosts
and mice challenged with soluble NP-OVA 24 hours later. Donor IgHb NP-specific antibodies
originating from ZBTB38 WT and KO mice were tracked over time. NP-specific antibody titers
were not altered with ZBTB38 deficiency (Figure 3.5B). Thus, ZBTB38 is also dispensable for
secondary B cell responses.
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3.4 Discussion
BTB-ZF family members such as BCL-6, ZBTB32, and ZBTB20, have demonstrated
critical roles in regulating different aspects of B cell responses. Our data demonstrate that
ZBTB38, another member of the BTB-POZ family, is dispensable for maintaining homeostasis
of lymphoid and myeloid hematopoietic lineages. In addition, ZBTB38 is also dispensable for
both primary and recall B cell responses to a hapten antigen. While hapten immunogens are
useful in studying B cell responses, they are not representative of B cell responses to protein
antigens. Thus, future studies should asses the role of ZBTB38 in regulating B cell responses to
protein antigens or pathogens. Not only is ZBTB38 highly expressed in different hematopoietic
lineages, it is also highly expressed in neurons. This suggests that ZBTB38 may have a role in
neuronal function.
Various models of ZBTB38 deletion or knockdown have resulted in impaired cellular
processes in neuronal injuries or tumors. For instance, increasing ZBTB38 expression reduces
apoptosis and promotes autophagy in a spinal cord injury model, and results in increased
21, 27, 28

neuronal repair

.

In contrast, ZBTB38 expression has been shown to promote

proliferation and differentiation of a neuroblastoma cell line

29

.

These differences in the

functional roles of ZBTB38 may be attributed varying sensitivity of different neurons to
oxidative stress

30

. ZBTB38, along with USP9X, a deubiquitinase, is required to limit basal

reactive oxidative species (ROS) levels and the response to oxidative stress

31

. Give the high

levels of ZBTB38 in neurons, perhaps ZBTB38 is involved with balancing neuronal death with
recovery after various challenges. To further understand the functional importance of ZBTB38
in various neurons, Zbtb38 f/f mice may be crossed to different neuron specific Cre mice and
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different neuronal function assessed. Neuronal insult, such as injury, stroke, or cancer may be
necessary to identify processes regulated by ZBTB38.
Genome-wide association studies in humans have identified single nucleotide
polymorphisms (SNPs) in ZBTB38 that are associated with shorter stature in Chinese
populations but taller stature in Korean populations

32, 33, 34, 35

. However, when Zbtb38 f/f mice

were crossed to CMV-Cre expressing mice, germline deletion of ZBTB38 did not result in
observable differences in the length or weight of the mice (data not shown).

Further

characterization of how SNPs influence ZBTB38 function, and identifying the location of SNPs,
may provide further explanation of why certain polymorphisms are associated with increased
height while other SNPs are associated with decreased height.
Together, our data indicate that ZBTB38 is likely not important for the development or
steady-state maintenance of hematopoietic lineages. In addition, primary and recall B cell
responses to a hapten antigen do not require ZBTB38. Of course, it remains possible that defects
exist in rare subsets of lineages that we did not analyze. Future studies focused on other cell
types can utilize the novel Zbtb38 f/f mice that we have generated.
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3.5 Methods
Mice.
All animal procedures used on mice were approved by the Animal Care and Use Committees at
Washington University and at the University of Arizona. All mice were housed and bred in
pathogen-free facilities. C57BL6/N mice were obtained from the National Cancer Institute.
B6.Cg-IghaThy1aGpi1a (IgHa) mice were obtained from Charles River Laboratories. ZBTB38f
embryonic stem cells were generated at the Genome Engineering and iPSC center at Washington
University School of Medicine and injected into B6 albino (Jackson Laboratory, stock no.
000058) mice by the Transgenic Knockout Microinjection Core facility at Washington
University in St. Louis. ZBTB38 f/f mice were crossed to CMV-Cre (Jackson Laboratory, stock
no. 006054) or VavCre (Jackson Laboratory, stock no. 008610) and maintained as ZBTB38 f/f
or ZBTB38 x CMV- or Vav-Cre where littermates were used as controls. The following primers
were

used

for

genotyping

the

Zbtb38

allele:

5’LoxP

forward

5’-

TCTGAGTTCAAGGCCAGCTT-3’, 5’LoxP reverse 5’- TCTCCAAGCAGAAAGGGTGT-3’,
and 3’LoxP reverse 5’- GGGTCGTTAGAGGATTCAGC-3’.

Immunizations.
Mice were immunized intraperitoneally with 100 μg NP-OVA (Biosearch), adjuvanted with
Alhydrogel (Invivogen). NP-APC used for staining was made by conjugating allophycocyanin
(Sigma-Aldrich)

with

4-hydroxy-3-nitrophenylacetyl-O-succinimide

Technologies).
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ester

(Biosearch

RNA extraction, cDNA synthesis, and qRT-PCR.
Total RNA was extracted with TRIzol (Life technologies) and cDNA synthesized using
Superscript III Reverse transcription kit with random hexamers (Life Technologies) according to
manufacturer’s instructions. qRT-PCR was performed using SYBR Green PCR master mix
(Applied Biosystems) on a Prism 7000 Sequence Detection System (Applied Biosystems). The
primers used for Zbtb38 are: forward 5’- AGAACCAAGGATTTCCGAGTG-3’ and reverse 5’GATGGAGAGTACTGTGTCACTG-3’.
ribosomal

RNA,

forward

Zbtb38 transript levels were normalized to 18S

5’-CGGCTACCACATCCAAGGAA-3’

and

reverse

5’-

GCTGGAATTACCGCGGCT-3’ 36.

ELISA.
ELISA plates (9018, Corning) were coated overnight at 4°C in 0.1 M sodium bicarbonate buffer,
pH 9.5 containing 5 ug/mL of NP16- or NP4-BSA (Bioresearch Technologies). All other
incubation steps were performed at room temperature for 1 hour. Wash steps were performed
between each step using PBS + 0.05% Tween-20. Plates were blocked with PBS + 2% BSA
followed by serial dilutions of serum. Serum was probed with 0.1 ug/mL of biotinylated antimouse IgG (715-065-151, Jackson ImmunoResearch Laboratories) and then detected with
streptavidin conjugated horseradish peroxidase (554066, BD biosciences).

Plates were

developed using TMB (Dako, S1599) and neutralized with 2N H2SO4. Optical density (OD)
values were measured at 450 nm. Serum endpoint titer was defined as the inverse dilution factor
that is three standard deviations above background using one-phase decay measurements and
Prism software (GraphPad Software).
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Adoptive transfer for recall responses.
Splenocytes from NP-immunized ZBTB38f/f or ZBTB38f/f x VavCre mice were isolated and
processed into single cell suspension.

erythrocytes lysed using an ammonium chloride-

potassium solution, and lymphocytes isolated by using a Hisopaque-1119 (Sigma-Aldrich)
density gradient. Cells were washed twice prior to transfer. 10% of cells were retained for
cellular analysis whereas the remaining 90% of cells were transferred into one non-irradiated
IgHa recipient mice by intravenous injection. A recall response was elicited by intravenously
challenging mice with soluble NP-OVA 24 hours later.

Flow cytometry.
Single cell suspensions were prepared from bone marrow or spleen, erythrocytes lysed using an
ammonium chloride-potassium solution, and lymphocytes isolated by using a Hisopaque-1119
(Sigma-Aldrich) density gradient. Cells were resuspended in PBS with 5% adult bovine serum
and 2 mM EDTA prior to staining with antibodies and NP-APC. The following antibodies were
purchased from Biolegend: 6D5 (CD19)-Alexa Fluor 700; GL7-FITC; 281-2 (CD138)-PE;
RMM-1 (IgM)-APC; 11-26c.2a (IgD)-PerCP-Cy5.5 or -Brilliant Violet 605; 16-10A1 (CD80)PE; RA3-6B2 (B220)-FITC, -Pacific Blue, or APC-Cy7; PO3 (CD86)-FITC; PK136 (NK-1.1)PerCP-Cy5.5; M1/70 (CD11b)-Pacific Blue; HK1.4 (Ly-6C)-Brilliant Violet 510; 1A8 (Ly-6G)Brilliant Violet 605; A7R34 (IL-7R)-Brilliant Violet 421; and E13-16.7 (Ly-6A/E)-PE. The
following antibodes were purchased from eBioscience: 11/41 (IgM)-PerCP-e710; 11-26c (IgD)FITC; 2B11 (CXCR4)-PerCP-e710; 2B8 (c-Kit)-PE-Cy7; and LG.7F9 (CD27)-APC.

The

following antibodies were purchased from BD Pharmingen: 53-6.7 (CD8a)-PE; RM4-5 (CD4)PE-Cy7; A2F10.1 (CD135)-PE-CF594; and 93 (CD16/CD32)-PerCP-Cy5.5.
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Cells were stained on ice for 20 minutes. Germinal center B cells were enriched by staining cells
with GL7-PE followed with anti-PE magnetic beads (0.5 uL/107 cells, Miltenyi Biotec). Positive
enrichment of GL7-expressing cells was performed using MACS LS columns (Miltenyi Biotec).

107

3.7 Acknowledgements
This work was supported by NIH grant R01AI099108 (D.B.). R.W. was supported by the NSF
Graduate Research Fellowship Program (DGE-1143954). We thank the Genome Engineering
and iPSC Center and the Transgenic Knockout Microinjection Core facility at Washington
University in St. Louis for assistance in generating Zbtb38 floxed mice.

108

3.7 References
1.

Purtha, W.E., Tedder, T.F., Johnson, S., Bhattacharya, D. & Diamond, M.S. Memory B
cells, but not long-lived plasma cells, possess antigen specificities for viral escape
mutants. Journal of Experimental Medicine 208, 2599-2606 (2011).

2.

Chevrier, S. & Corcoran, L.M. BTB-ZF transcription factors, a growing family of
regulators of early and late B-cell development. Immunology and cell biology 92, 481488 (2014).

3.

Dhordain, P. et al. Corepressor SMRT binds the BTB/POZ repressing domain of the
LAZ3/BCL6 oncoprotein. Proceedings of the National Academy of Sciences of the
United States of America 94, 10762-10767 (1997).

4.

Dhordain, P. et al. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone
deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res
26, 4645-4651 (1998).

5.

Hong, S.H., David, G., Wong, C.W., Dejean, A. & Privalsky, M.L. SMRT corepressor
interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and
PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia.
Proceedings of the National Academy of Sciences of the United States of America 94,
9028-9033 (1997).

6.

Wong, C.-W. & Privalsky, M.L. Components of the SMRT Corepressor Complex Exhibit
Distinctive Interactions with the POZ Domain Oncoproteins PLZF, PLZF-RARα, and
BCL-6. Journal of Biological Chemistry 273, 27695-27702 (1998).

7.

Ye, B.H. et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2type inflammation. Nature Genetics 16, 161-170 (1997).

8.

Wang, Y. & Bhattacharya, D. Adjuvant-specific regulation of long-term antibody
responses by ZBTB20. The Journal of experimental medicine 211, 841 (2014).

9.

Chevrier, S. et al. The BTB-ZF transcription factor Zbtb20 is driven by Irf4 to promote
plasma cell differentiation and longevity. The Journal of experimental medicine 211, 827
(2014).

10.

Jash, A. et al. ZBTB32 Restricts the Duration of Memory B Cell Recall Responses.
Journal of immunology 197, 1159-1168 (2016).

11.

Jash, A. et al. ZBTB32 restrains antibody responses to murine cytomegalovirus
infections, but not other repetitive challenges. Scientific Reports 9, 15257 (2019).

12.

Ocskó, T. et al. Transcription factor Zbtb38 downregulates the expression of antiinflammatory IL1r2 in mouse model of rheumatoid arthritis. Biochimica et Biophysica
Acta (BBA) - Gene Regulatory Mechanisms 1861, 1040-1047 (2018).
109

13.

Filion, G.J.P. et al. A family of human zinc finger proteins that bind methylated DNA
and repress transcription. Molecular and cellular biology 26, 169-181 (2006).

14.

Sasai, N., Matsuda, E., Sarashina, E., Ishida, Y. & Kawaichi, M. Identification of a novel
BTB-zinc finger transcriptional repressor, CIBZ, that interacts with CtBP corepressor.
Genes to cells : devoted to molecular & cellular mechanisms 10, 871-885 (2005).

15.

Sasai, N., Nakao, M. & Defossez, P.-A. Sequence-specific recognition of methylated
DNA by human zinc-finger proteins. Nucleic Acids Res 38, 5015-5022 (2010).

16.

Miotto, B. et al. The RBBP6/ZBTB38/MCM10 axis regulates DNA replication and
common fragile site stability. Cell reports 7, 575-587 (2014).

17.

Oikawa, Y. et al. The methyl-CpG-binding protein CIBZ suppresses myogenic
differentiation by directly inhibiting myogenin expression. Cell research 21, 1578-1590
(2011).

18.

Nishii, T., Oikawa, Y., Ishida, Y., Kawaichi, M. & Matsuda, E. CtBP-interacting BTB
zinc finger protein (CIBZ) promotes proliferation and G1/S transition in embryonic stem
cells via Nanog. The Journal of biological chemistry 287, 12417-12424 (2012).

19.

Kotoku, T. et al. CIBZ Regulates Mesodermal and Cardiac Differentiation of by
Suppressing T and Mesp1 Expression in Mouse Embryonic Stem Cells. Scientific reports
6, 34188-34188 (2016).

20.

Oikawa, Y., Matsuda, E., Nishii, T., Ishida, Y. & Kawaichi, M. Down-regulation of
CIBZ, a novel substrate of caspase-3, induces apoptosis. The Journal of biological
chemistry 283, 14242-14247 (2008).

21.

Cai, Y. et al. CIBZ, a novel BTB domain-containing protein, is involved in mouse spinal
cord injury via mitochondrial pathway independent of p53 gene. PloS one 7, e33156
(2012).

22.

Spangrude, G.J., Heimfeld, S. & Weissman, I.L. Purification and characterization of
mouse hematopoietic stem cells. Science 241, 58 (1988).

23.

Kondo, M., Weissman, I.L. & Akashi, K. Identification of Clonogenic Common
Lymphoid Progenitors in Mouse Bone Marrow. Cell 91, 661-672 (1997).

24.

Akashi, K., Traver, D., Miyamoto, T. & Weissman, I.L. A clonogenic common myeloid
progenitor that gives rise to all myeloid lineages. Nature 404, 193-197 (2000).

25.

Weisel, F.J., Zuccarino-Catania, G.V., Chikina, M. & Shlomchik, M.J. A Temporal
Switch in the Germinal Center Determines Differential Output of Memory B and Plasma
Cells. Immunity 44, 116-130 (2016).

26.

Shi, W. et al. Transcriptional profiling of mouse B cell terminal differentiation defines a
signature for antibody-secreting plasma cells. Nature immunology 16, 663-673 (2015).
110

27.

Cai, Y. et al. Zbtb38 is a novel target for spinal cord injury. Oncotarget 8 (2017).

28.

Chen, J. et al. ZBTB38, a novel regulator of autophagy initiation targeted by
RB1CC1/FIP200 in spinal cord injury. Gene 678, 8-16 (2018).

29.

Chen, J. et al. Transcriptome profiling reveals the role of ZBTB38 knock-down in human
neuroblastoma. PeerJ 7, e6352 (2019).

30.

Wang, X. & Michaelis, E. Selective neuronal vulnerability to oxidative stress in the brain.
Frontiers in Aging Neuroscience 2 (2010).

31.

Miotto, B. et al. Stabilization of the methyl-CpG binding protein ZBTB38 by the
deubiquitinase USP9X limits the occurrence and toxicity of oxidative stress in human
cells. Nucleic Acids Res 46, 4392-4404 (2018).

32.

Cho, Y.S. et al. A large-scale genome-wide association study of Asian populations
uncovers genetic factors influencing eight quantitative traits. Nature Genetics 41, 527534 (2009).

33.

Gudbjartsson, D.F. et al. Many sequence variants affecting diversity of adult human
height. Nature Genetics 40, 609-615 (2008).

34.

Kim, J.-J. et al. Exome sequencing and subsequent association studies identify five amino
acid-altering variants influencing human height. Human Genetics 131, 471-478 (2012).

35.

Wang, Y. et al. An SNP of the ZBTB38 gene is associated with idiopathic short stature in
the Chinese Han population. Clinical Endocrinology 79, 402-408 (2013).

36.

Chou, C. et al. c-Myc-induced transcription factor AP4 is required for host protection
mediated by CD8+ T cells. Nature immunology 15, 884-893 (2014).

111

Figure 3.1 Zbtb38 targeting strategy and confirmation of deletion.
(A) Targeting construct of Zbtb38 exon 3. NdeI and EcoRI restriction sites were introduced to
allow for screening of plasmid integration. (B) PCR showing that exon 3 is correctly targeted.
Lane 1 is the undigested PCR product, lane 2 is a NdeI digest (expected band sizes of 5.8 kb
and 445 bp), lane 3 is a EcoRI digest (expected band sizes of 2.6 kb, 2 kb, and 1.6 kb), and
lane 4 is a NdeI and EcoRI double digest (expected band sizes of 445 bp, 2.1 kb, 2 kb, and 1.6
kb). (C) PCR showing that Zbtb38 can be deleted upon Cre activity. Primers used are the
same ones used to amplify the genomic DNA in (B). (D) Genotyping strategy to identify if a
mouse has the WT, floxed, or deleted Zbtb38 allele.
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Figure 3.2 ZBTB38 deficiency does not alter the development of hematopoietic cells.
(A) ZBTB38 expression values in select cell subsets were extracted from ImmGen’s RNA-seq
SKYLINE and grouped based on cell type. Cell types shown have a ZBTB38 expression
value, normalized by DESeq2, of 800 or greater. (B) The frequencies of hematopoietic stem
cells
(HSCs,
cKit+Sca1+Flk2-CD27+),
multi-potent
progenitors
(MPPs,
+
+
+
+
+
+
cKit Sca1 Flk2 CD27 ), common myeloid progenitors (CMPs, cKit Sca1 Flk2 FcgR-),
granulocyte monocyte progenitors (GMPs, cKit+Sca1-Flk2-FcgR+), and common lymphoid
progenitors (CLPs, cKit-/loSca1-CD27+FcgR-Flk2+IL7Ra+) in the bone marrow from ZBTB38
WT and KO mice were quantified by flow cytometry. Mean ± SEM are shown; each symbol
represents an individual mouse. Statistical significance was determined by unpaired student’s
2-tailed t-test; n.s. indicates no significance (p > 0.05). Data shown are from one experiment.
(C) The frequencies of B cells (B220+), natural killer (NK, NK1.1+) cells, CD4+ and CD8+ T
cells
(B220-CD11b-NK.1-),
monocytes
(CD11b+Ly6ChiLy6G-),
and
neutrophils
+
+
+
(CD11b Ly6C Ly6G ) of peripheral blood mononuclear cells (PBMCs) from ZBTB38 WT
and KO mice were quantified by flow cytometry. Mean ± SEM are shown; each symbol
represents an individual mouse. Statistical significance was determined by unpaired student’s
2-tailed t-test; n.s. indicates no significance (p > 0.05). Data shown are from one experiment.
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Figure 3.3 ZBTB38 expression level in select B cell subsets.
Naïve B cells, antigen-specific dark (DZ, CXCR4+) and light (LZ, CD86+) zone germinal
center B cells (GCBC, CD19+GL7+IgD-), and splenic plasma cells (SpPC, CD138+) were
sorted and Zbtb38 RNA levels quantified by quantitative real time PCR. Zbtb38 expression
level was first normalized to 18S expression level followed by normalization to naïve B cells.
Mean ± SEM are shown; each symbol represents an individual mouse. Data shown are from
one experiment.
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Figure 3.4 ZBTB38 deficiency does not impair primary B cell responses.
(A) ZBTB38 WT and KO mice were immunized with NP-OVA and the frequency of NPspecific germinal center B cells two weeks post immunization was quantified by flow
cytometry. Mean ± SEM are shown; each symbol represents an individual mouse. Statistical
significance was calculated by unpaired student’s two-tailed t-test; n.s. = not significant (p >
0.05). (B, C) ZBTB38 WT and KO mice were immunized with NP-OVA and total serum
antibody titers (B) and high affinity serum antibody titers (C) to NP were quantified by ELISA.
Endpoint titers are calculated as the reciprocal serum dilution that was three standard
deviations above background. Mean ± SEM are shown; each symbol represents an individual
mouse. Statistical significance was calculated by Mann-Whitney test; n.s. = not significant (p
> 0.05). (D) Affinity maturation of the antibodies was calculated as the ratio of endpoint titers
to NP4 : NP16 and plotted at each time point for ZBTB38 WT and ZBTB38 KO mice. Mean ±
SEM are shown; each symbol represents an individual mouse. (E) The frequency of NPspecific long-lived plasma cells was calculated by flow cytometry. The long-lived plasma
cells were analyzed 8 weeks post-NP immunization. Mean ± SEM are shown; each symbol
represents an individual mouse. Statistical significance was calculated by unpaired student’s
two-tailed t-test; n.s. = not significant (p > 0.05). Data shown are from one experiment.
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Figure 3.5 Recall responses to NP do not require ZBTB38.
(A) The frequency of NP-specific memory B cells (CD19+GL7-IgM-IgD-CD80+CCR6+) was
quantified by flow cytometer in ZBTB38 WT and KO mice 8 weeks after NP-OVA
immunization. Mean ± SEM are shown; each symbol represents an individual mouse.
Statistical significance was calculated by unpaired student’s two-tailed t-test; n.s. = not
significant (p > 0.05). Data shown is from one experiment. (B) Splenocytes from ZBTB38
WT and ZBTB38 KO mice were adoptively transferred into IgHa naïve hosts and challenged
with soluble NP-OVA one day after transfer. Donor (IgHb) antibody responses were
calculated as the endpoint titer against high density NP. Mean ± SEM are shown; each symbol
represents an individual mouse. Statistical significance was calculated by Mann-Whitney test;
n.s. = not significant (p > 0.05). Data shown is from one experiment.
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Chapter 4:
Discussion
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In this study, we characterized the generation and utilization of diverse memory B cells in
their native environment following heterologous flavivirus challenges, and thus provide an
etiological explanation for the existence of memory B cells. A primary flavivirus challenge
generates flavivirus-specific long-lived plasma cells (LLPCs) but broadly reactive memory B
cells (MBCs). These broadly reactive MBCs respond to a secondary heterologous challenge
without undergoing further affinity maturation. Therefore, we propose that MBCs have been
evolutionarily selected for in order to provide anticipatory protection against antigens that have
evaded neutralization by serum antibodies and heterologous pathogen. This in turns provides
more rapid protection against the secondary pathogen compared to a naïve B cell response.
While our study contributes to a better understanding of how MBCs are generated and utilized,
future work should clarify whether GC-biased MBCs can even be engaged during recall
responses and to mechanistically define cues that promote the differentiation of MBCs from GC
B cells.
Analysis of MBC subsets in WNV vaccinated mice identified DIII-specificity exclusively
in the CD80+, plasma cell-biased MBC subset (Figure 2.5A). Thus, this observation cannot
definitively exclude the possibility that the lack of GCs after a secondary heterologous challenge
is due to the absence of GC-biased MBCs. Preliminary analysis of MBC subsets in WNV
infected mice identified the existence of both plasma cell-biased and GC-biased MBCs. Future
work using WNV infection followed by JEV infection is necessary to more conclusively show
that MBCs generated after a primary flavivirus infection respond to heterologous infection by
directly differentiating into plasma cells to provide protection. Although we utilized DENV and
ZIKV sequential infections to further support that MBCs do not require further affinity
maturation to respond to heterologous antigens (Figure 2.3G), we did not analyze the
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distribution of DENV-specificity in different MBC subsets prior to ZIKV infection. Thus, it is
unclear if the DENV infection generated GC-biased MBCs that could be potentially engaged
upon secondary challenge. Should a primary infection result in the engagement of GC-biased
MBCs upon a heterologous secondary infection, further studies clarifying signals that promote
the differentiation of GC-biased versus plasma cell-biased MBCs, as well as their antigen
specificities, are necessary. Such signals may originate from the cytokine milieu and/or strength
of BCR signaling.
Irrespective of the ability of GC-biased MBCs to be engaged during secondary recall
responses, it remains to be seen how MBCs respond to a tertiary flavivirus challenge. Secondary
flavivirus challenges result in the activation of cross-reactive MBCs, of which a minority binds
the neutralizing LR epitope. Thus, how do neutralizing and non-neutralizing antibodies derived
from cross-reactive MBCs impact tertiary heterologous challenges? Will ADE of the tertiary
challenge occur? Will original antigenic sin occur by further activating cross-reactive MBCs
that responded to the secondary heterologous challenge, or will a tertiary heterologous challenge
activate a different subset of cross-reactive MBCs generated after the primary challenge? To
address these questions, the MBC and antibody specificities after a tertiary challenge need to be
assessed. This is important for better understanding how the breadth of MBCs is utilized upon
sequential challenges.
In addition to understanding how MBCs respond to tertiary heterologous challenges, it is
important to understand how disparate antigens have to be in order to bypass MBC reactivation
and initiate naïve B cells responses. Our data indicate that sequential challenges between
flaviviruses that are approximately 55% and 75% similar at the DIII amino acid sequence level
do not require additional affinity maturation to generate cross-reactive antibodies (Figure 2.2).
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Thus, it remains to be seen if flaviviruses that are more disparate can still initiate cross-reactive
responses. To address this, future experiments secondary challenges utilizing flaviviruses that
are more or less disparate than the primary challenge are necessary. For instance, what is the
response between a St. Louis Encephalitis Virus (SLEV) primary challenge and a Dengue virus
(DENV) secondary challenge, where SLEV and DENV share approximately 40% DIII sequence
identity?
Thus far, we have focused on the utilization of MBCs upon recall challenge. However, it
is still unclear what cues promote the MBC fate. Two mechanisms for MBC differentiation have
been proposed. One is the temporal switch in which GCs go from supporting MBC fate during
early reactions to supporting LLPC fate during late reactions 1. The other is the selection of low
affinity GC B cells into the MBC compartment due to weaker T cell help, and thus elevated
levels of Bach2 2.

While these two mechanisms are not completely mutually exclusive,

especially during early GC reactions, it is unclear how GC environments change over time, and
how that in turn impacts GC B cell selection, affinity maturation, and differentiation. Here, we
demonstrate that a continuous, but active, selection of relatively low affinity germinal centers
into the MBC compartment likely promotes the diversity of MBCs (Figure 2.14F). The active
selection conclusion is based on the significant enrichment of MBCs for DIII-nonLR specificity
compared to their GC B cell precursors (Figure 2.6C). In addition, DIII-nonLR specific GC B
cells were enriched for MBC precursor surface markers (Figure 2.6D). Thus, DIII-nonLR
specificity can perhaps be used as a surrogate marker for an ultimate MBC fate, and thus aid in
identifying signals that promote the MBC fate.
Additionally, it is necessary to have a better understanding of how DIII-nonLR and DIIILR specific cells differ, and why DIII-nonLR specificity is predominately found in MBCs and
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not LLPCs.

One hypothesis is that DIII-nonLR specific cells perhaps have different

transcriptional or chromatin-accessibility signatures relative to DIII-LR specific cells. In this
case, single cell RNA- and ATAC-sequencing over time may provide clues to why DIII-nonLR
specific cells are predisposed towards the MBC fate. We would expect that DIII-nonLR specific
cells have a greater MBC signature than DIII-LR specific cells. Alternatively, perhaps DIIInonLR specific GC B cells are constantly of lower affinity compared to DIII-LR specific GC B
cells. Bulk VDJ sequencing of the heavy chain from WNV DIII-LR and -nonLR specific GC B
cells over time identified a reduced mutational load in DIII-nonLR specific cells (data not
shown). However, analysis of DIII-LR and DIII-nonLR MBC-derived mAbs did not reveal
binding differences to WNV WT DIII. Thus, it is inconclusive if DIII-nonLR specific GC B
cells are of consistently lower affinity or not. To test this, monoclonal antibodies from GC B
cells over time need to be produced. Or over time, DIII-specific GC B cells from WNV
vaccinated Nur77 reporter mice can be analyzed for GFP expression, which corresponds to
strength of BCR signaling. Yet another hypothesis for why DIII-nonLR specific cells are
enriched in the MBC compartment is that DIII-LR and -nonLR specific cells are differentially
sensitive to BCR stimulation. Analysis of Hardy Fractions E and F revealed a slight reduction in
surface IgM levels in Fraction E DIII-LR cells compared to DIII-nonLR cells, although this
reduction was not maintained in the recirculating mature Fraction F population. Given that
lower surface IgM levels correlate with anergy, and that anergic B cells can still participate in
GC reactions 3, perhaps DIII-LR specific cells require a higher activation threshold for
differentiation. To test this, calcium flux assays can be performed using different concentrations
of DIII.

What we would expect is that DIII-LR specific cells would require a higher

concentration of DIII to generate a calcium flux compared to DIII-nonLR specific cells.
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Although our study focuses on flaviviruses infections, it can be applied to different
infections. In the context of flaviviruses, we propose that the diversity of MBCs may negatively
impact the host response towards heterologous challenges due to the increased likelihood of
generating poorly neutralizing but broadly reactive antibodies, which in turn may promote ADE.
The inability of MBCs to remodel their specificity towards new antigens by re-initiating GC
reactions indicates that the primary response is critical for defining secondary responses. Thus,
vaccine efforts should focus on two aspects: 1) limit the diversity of MBCs and 2) focus
responses towards neutralizing epitopes that are type specific. However, for rapidly mutating
pathogens such as influenza, a diverse MBC compartment may be beneficial.
The constantly evolving nature of influenza, especially at the hemagglutinin (HA) head,
means that neutralizing anti-HA head antibody responses to one influenza strain is unlikely to
neutralize another strain. Thus, current vaccine efforts have focused on mounting antibody
responses against the conserved HA stem region. Careful analysis of newly generated and preexisting MBCs after secondary influenza exposure revealed the inability of stem-reactive MBCs
to affinity mature 4. These findings corroborate our findings where MBCs do not undergo
further affinity maturation after re-activation.

In the context of influenza infections, we

hypothesize that MBC diversity may be beneficial to the host since it increases the likelihood of
recognizing variant antigens, especially at the conserved hemagglutinin (HA) stem region. Thus,
we propose that influenza vaccine strategies should focus on generating a broadly reactive
primary MBC pool that has the potential to recognize multiple variants, either at the HA head or
stem. Immunogen design, such as hyperglycosylation of the HA head, may aid in focusing the
MBC response towards stem epitopes by increasing the accessibility of the HA stem during a
primary exposure 5.
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Our findings can also be applied to another problematic pathogen, HIV. HIV also
constantly evolves over time where broadly neutralizing antibodies are associated with high
levels of somatic hypermutation. Current vaccine strategies focus on guiding the B cell response
through sequential immunizations with variant antigens or by targeting public clonotypes 6.
These strategies rely on the re-initiation of GCs by MBCs to further somatically hypermutate
their BCRs. However, our data indicate that MBCs are unable to further affinity mature.
Therefore, sequential activation of MBCs in hopes of re-initiating GCs and further somatically
hypermutate BCRs to generate broadly neutralizing antibodies (bnAbs) is likely an ineffective
strategy. Instead, perhaps modifying the timing of antigenic challenges to ensure persistent GCs
is a more effective strategy at generating bnAbs.
The data from this study further expand the etiological role of MBCs to not only
recognizing pathogen escape variants but also heterologous antigens. Our data suggest that the
diversity of MBCs results from the continued active selection of lower affinity GC B cells into
the MBC compartment. Furthermore, the diversity of MBCs generated after a primary challenge
is broad enough that further molding of the BCR towards new specificities via GC reactions is
unnecessary after a secondary heterologous exposure. Remaining questions include identifying
the cues that are necessary to promote the preferential differentiation of broadly reactive GC B
cells into the MBC compartment as well as determining if GC-biased MBCs can be activated
upon recall in the presence of antigen-specific antibodies. A better understanding of these
processes has different implications for vaccine development for multiple pathogens, such as
flaviviruses, influenza, and HIV.

123

4.1 References
1.

Weisel, F.J., Zuccarino-Catania, G.V., Chikina, M. & Shlomchik, M.J. A Temporal
Switch in the Germinal Center Determines Differential Output of Memory B and Plasma
Cells. Immunity 44, 116-130 (2016).

2.

Shinnakasu, R. et al. Regulated selection of germinal-center cells into the memory B cell
compartment. Nature immunology advance on, 861-869 (2016).

3.

Burnett, D.L. et al. Germinal center antibody mutation trajectories are determined by
rapid self/foreign discrimination. Science (New York, N.Y.) 360, 223-226 (2018).

4.

Andrews, S.F. et al. Activation Dynamics and Immunoglobulin Evolution of Pre-existing
and Newly Generated Human Memory B cell Responses to Influenza Hemagglutinin.
Immunity 51, 398-410.e395 (2019).

5.

Eggink, D., Goff, P.H. & Palese, P. Guiding the Immune Response against Influenza
Virus Hemagglutinin toward the Conserved Stalk Domain by Hyperglycosylation of the
Globular Head Domain. Journal of virology 88, 699 (2014).

6.

Stamatatos, L., Pancera, M. & McGuire, A.T. Germline-targeting immunogens.
Immunological reviews 275, 203-216 (2017).

124

